US20100137435A1 - Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis - Google Patents
Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis Download PDFInfo
- Publication number
- US20100137435A1 US20100137435A1 US12/640,875 US64087509A US2010137435A1 US 20100137435 A1 US20100137435 A1 US 20100137435A1 US 64087509 A US64087509 A US 64087509A US 2010137435 A1 US2010137435 A1 US 2010137435A1
- Authority
- US
- United States
- Prior art keywords
- compound
- cells
- cancer
- day
- treated group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title abstract description 31
- 206010040047 Sepsis Diseases 0.000 title abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 71
- -1 acetyl diacyl glycerol Chemical class 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 32
- 201000001441 melanoma Diseases 0.000 claims description 15
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 206010004593 Bile duct cancer Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 85
- 210000004443 dendritic cell Anatomy 0.000 abstract description 51
- 230000000694 effects Effects 0.000 abstract description 36
- 235000013402 health food Nutrition 0.000 abstract description 21
- 239000004615 ingredient Substances 0.000 abstract description 21
- 230000036039 immunity Effects 0.000 abstract description 19
- 210000003056 antler Anatomy 0.000 abstract description 18
- 230000004083 survival effect Effects 0.000 abstract description 16
- 241000699800 Cricetinae Species 0.000 abstract description 15
- 206010040070 Septic Shock Diseases 0.000 abstract description 14
- 230000036303 septic shock Effects 0.000 abstract description 13
- 239000002955 immunomodulating agent Substances 0.000 abstract description 12
- 210000001616 monocyte Anatomy 0.000 abstract description 11
- 230000002708 enhancing effect Effects 0.000 abstract description 9
- 241000282994 Cervidae Species 0.000 abstract description 8
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 8
- 230000003013 cytotoxicity Effects 0.000 abstract description 8
- 210000002865 immune cell Anatomy 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 8
- 230000003213 activating effect Effects 0.000 abstract description 6
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 5
- 230000001629 suppression Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000008102 immune modulation Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000003111 delayed effect Effects 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 229940126214 compound 3 Drugs 0.000 description 116
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 32
- 210000001744 T-lymphocyte Anatomy 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 29
- 108010002350 Interleukin-2 Proteins 0.000 description 28
- 102000000588 Interleukin-2 Human genes 0.000 description 28
- TZSMWSKOPZEMAJ-UHFFFAOYSA-N bis[(2-methoxyphenyl)methyl] carbonate Chemical compound COC1=CC=CC=C1COC(=O)OCC1=CC=CC=C1OC TZSMWSKOPZEMAJ-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- 230000001965 increasing effect Effects 0.000 description 24
- 239000006166 lysate Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 20
- 108090000695 Cytokines Proteins 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 16
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 229940124644 immune regulator Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 5
- 102100032817 Integrin alpha-5 Human genes 0.000 description 5
- 102100022339 Integrin alpha-L Human genes 0.000 description 5
- 108010041014 Integrin alpha5 Proteins 0.000 description 5
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 5
- 101100452019 Mus musculus Icam2 gene Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 244000299461 Theobroma cacao Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003714 granulocyte Anatomy 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 4
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 4
- 241000699673 Mesocricetus auratus Species 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000015895 biscuits Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000002635 electroconvulsive therapy Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 235000009470 Theobroma cacao Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 0 [1*]OCC(COC(C)=O)O[2*] Chemical compound [1*]OCC(COC(C)=O)O[2*] 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- BFGDEKPANYJEBP-HNENSFHCSA-N (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (z)-octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC BFGDEKPANYJEBP-HNENSFHCSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- ANPHHFSIESCNSY-UHFFFAOYSA-N 1-palmitoyl-2-arachidonoyl-3-acetylglycerol Natural products CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCC=CCC=CCC=CCC=CCCCCC ANPHHFSIESCNSY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UCLAKHRTNSBSRH-UHFFFAOYSA-N 1-palmitoyl-2-linolenoyl-3-acetylglycerol Natural products CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCCC=CCC=CCC=CCC UCLAKHRTNSBSRH-UHFFFAOYSA-N 0.000 description 1
- BFGDEKPANYJEBP-UHFFFAOYSA-N 1-palmitoyl-2-oleoyl-3-acetylglycerol Natural products CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCCC=CCCCCCCCC BFGDEKPANYJEBP-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GAKUNXBDVGLOFS-DUZKARGPSA-N CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC(COC(C)=O)COC(=O)CCCCCCCCCCCCCCC Chemical compound CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC(COC(C)=O)COC(=O)CCCCCCCCCCCCCCC GAKUNXBDVGLOFS-DUZKARGPSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 241000283007 Cervus nippon Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- GAKUNXBDVGLOFS-UHFFFAOYSA-N PLA Natural products CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCCC=CCC=CCCCCC GAKUNXBDVGLOFS-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005852 acetolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 125000002886 arachidonoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 108010006989 estrone receptor Proteins 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000002748 hepatotoxicity test Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000019690 meat sausages Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000003713 septic shock treatment agent Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940124594 traditional oriental medicine Drugs 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/14—Organic oxygen compounds
- A21D2/16—Fatty acid esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to uses of immunomodulating agent, medical supplies, and health foods containing mono acetyl diacyl glycerol derivatives extracted from deer antler as an effective ingredient.
- Antler in Latin, Cervi parvum cornu is an uncalcified horn harvested and dried from any animal of the deer family.
- deer antlers together with ginseng have been widely used for their various acclaimed medicinal effects.
- the deer family for the traditional use of antlers are limited only Cervus nippon Temminick var. mantchuricus Swinhoe (Referred as C.N. hereafter) and Cervus elaphus L. Deer antler has been acclaimed to have numerous medicinal effects.
- Immunity is a defense mechanism protecting a living body from various pathogens. Immunodeficiency is resulted from a defect in a constituent of immune system, indicating that immune system is unable to response to various antigens. Immunodeficiency is largely divided into congenital or primary immunodeficiency and acquired or secondary immunodeficiency. In the case of congenital immunodeficiency, B-cells or T-cells do not exist naturally, so it can be treated only by gene therapy, antibody insertion and bone marrow transplantation. On the other hand, in the case of acquired immunodeficiency, all the immune related factors exist naturally but there is malfunctioning in immune response, so it can be improved by promoting the functions of immune factors.
- autoimmune diseases such as arthritis, atopy, dementia and sepsis have been increased.
- Autoimmune diseases are resulted from over increasing of immune function.
- An immune suppressor has been used to remedy autoimmune diseases, but the immune suppressor also causes decreasing of immunity frequently.
- various attempts have been made to develop an immune regulator for the control of immunity. The purpose of these attempts is for increasing defensive power of a living body against pathogens and minimizing side-effects by controlling promotion or suppression of immune function with immune regulators which can stimulate immune cells non-specifically.
- Immune regulators can remedy almost diseases of living body such as cancer, sepsis, degenerative arthritis, infection, dementia, aging, diabetes, anemia, skin disease, asthma, atopy, stress, nerve breakdown, physical fatigue, chronic fatigue syndrome, and osteoporosis.
- chemical compounds, microorganism compositions, biological products, etc have been used as an immune regulator.
- Most of those immune regulators are limited in using because they are inclined to work only one effect (either immune promotion or suppression). Therefore, they may cause side effects and have toxicity themselves.
- foodstuffs without toxicity, effective ingredients extracted from natural sources and the traditional herb medicines are the major targets to develop immune regulators and experiments to examine their effects as a medicine have been on trial. But these immune regulators still have either immune promotion or suppression effect.
- the present inventors separated various ingredients of C.N. antler which has been known to having excellent pharmaceutical effects as a folk remedy, and further observed that one of those effective ingredients of C.N. antler, mono acetyl diacyl glycerol, showed significant immune regulation activity in vivo.
- the C.N. antler has a possibility of using for septic shock treatment and anti-cancer agent without causing toxicity in vivo.
- the present inventors completed this invention by confirming that mono acetyl diacyl glycerol of the invention can be used as a safe immune enhancing agent, an immunomodulating agent, a septic shock treatment and an anti-cancer agent.
- an object of the present invention to provide an immunomodulating agent, a septic shock treatment, an anti-cancer agent, and health foods containing mono acetyl diacyl glycerol derivatives as an effective ingredient.
- Health foods are for modulating immune, preventing or treating septic shock and cancer.
- the present invention provides an immunomodulating agent containing mono acetyl diacyl glycerol derivatives represented by the following formula 1 as an effective ingredient.
- R1/R2 is 9-octadecenoyl(oleoyl)/hexadecanoyl(palmitoyl), hexadecanoyl (palmitoyl)/(9-octadecenoyl(oleoyl), hexadecanoyl(palmitoyl)/9,12-octadecadienoyl(linoleoyl), hexadecanoyl(palmitoy1)/9,12,15-octadecatrienoyl (linolenoyl) or hexadecanoyl(palmitoyl)/5,8,11,14-eicosatetraenoyl(arachidonoyl).
- the present invention also provides an AIDS treatment, a sepsis treatment, and an anti-cancer agent containing mono acetyl diacyl glycerol derivatives of formula 1 as an effective ingredient.
- the present invention further provides health foods containing mono acetyl diacyl glycerol derivatives of formula 1 as an effective ingredient for an immune modulation or the prevention of cancer.
- FIG. 1 is a set of photographs showing the T-cell (T-4 and T-8) activity of control group, IL-2 treated group (20 ng/ml), and Compound 3 treated group (1 ⁇ g/ml). Each number indicates the number of spots capturing IL-2 specific antibody.
- FIG. 2 is a graph showing the release of cytokines when T lymphocytes are activated by Compound 3,
- Control group anti-CD3, anti-CD28 treated,
- FIG. 3 is a set of photographs showing the morphology of mouse dendritic cells derived from mouse bone marrow cells after the treatment of GM-CSF (20ng/m1), IL-4(20 ng/ml) and TNF- ⁇ (5 ng/ml).
- A a microscopic photograph taken right after the inoculation of mouse bone marrow cells with the density of 1 ⁇ 10 6 cells/ml ( ⁇ 100).
- D a microscopic photograph of the dendritic cells which are forming specific small and long protrusions on the 9th day of culture ( ⁇ 1000), the small photograph is the enlarged photograph of the specific cell ( ⁇ 2).
- FIG. 4 is a set of graphs showing the results of FACS analyzing the expressions of the dendritic cell specific markers, a monocyte specific marker and a granulocyte specific marker on the 11th day of culture of bone marrow cells separated from Balb/c AnN mouse. (Here, staining of isomer control against hamster's IgG and rat's IgG2a is used for a setting marker line (straight line).
- CD80 and CD86 as co-stimulation specific markers
- CD11c and DEC-205 as dendritic cell specific markers
- CD14 and F4/80 as monocyte/macrophage specific markers
- Gr-1 as a granulocyte specific marker.
- FIG. 5 is an electrophoresis photograph showing the effects of Compound 3 on dendritic cells on the expression of adhesion molecules.
- Lane 1 Vcam-1 Lane 2: Icam-1 Lane 3: Icam-2 Lane 4: VLA-4 Lane 5: VLA-5 Lane 6: LFA-1 Lane 7: GAPDH (+): Compound 3 treated group ( ⁇ ): Control group.
- FIG. 6 is a set of photographs showing the results of tumor forming at the near injection site, 4 weeks after tumor (KIGB-5) i.v. injection and processing with different condition.
- A RPMI control group B: BMSC treated group
- FIG. 7 is a set of photographs showing the results of tumor forming at the near injection site, 8 weeks after tumor (KIGB-5) i.v. injection and processing with different condition.
- FIGS. 8 and 9 are a set of photographs showing the gross and microscopic findings of metastatic lung lesions of each group, 8 weeks after tumor (KIGB-5) i.v. injection.
- FIG. 10 is a set of photographs showing the lung tumors and its size of each group, 12 weeks after tumor (KIGB-5) s.c(subcutaneously) injection.
- G Compound 3 (25 mg/kg/day) treated group.
- FIG. 11 is a set of photographs showing gross findings of metastatic lung lesions of each group of Syrian golden hamsters treated with various doses of Compound 3, 8 weeks after biliary cancer cell((5 ⁇ 10 5 cells) injection.
- FIG. 12 is a set of photographs showing microscopic findings of metastatic lung lesions of each group of Syrian golden hamsters treated with various doses of Compound 3, 8 weeks after biliary cancer cell((5 ⁇ 10 5 cells) injection.
- FIG. 13 is a set of photographs showing gross findings of metastatic lung lesions of each of C57B1/6 mice received various treatments, 4 weeks after melanoma cells (2 ⁇ 10 4 cells) i.v. injection.
- FIG. 14 is a set of photographs showing microscopic findings of metastatic lung lesions of each of C57B1/6 mice received various treatments, 4 weeks after melanoma cells (2 ⁇ 10 4 cells) i.v. injection.
- FIG. 15 is a graph showing survival rate of each treated group during 6 weeks after melanoma cells. (2 ⁇ 10 4 cells) i.v. injection.
- FIG.16 is a graph showing the cytotoxicity of T lymphocytes activated by Compound 3 on melanoma cells.
- Control 1 anti-CD3, anti-CD28 treated group
- Control 2 anti-CD3, anti-CD28, and IL-2 (20 ng/ml) treated group
- the present invention provides an immunomodulating agent, an AIDS treatment, a sepsis treatment, and an anti-cancer agent containing mono acetyl diacyl glycerol derivatives represented by the following formula 1 as an effective ingredient.
- the compound represented by formula 1 of the present invention is one of following 5 compounds:
- the compound of the present invention was extracted from C.N. antlers or manufactured by conventional organic synthesis method.
- the exemplary of extraction method has the following steps. Particularly, the chloroform extracts of C.N. antler are obtained by extracting C.N. antler with hexane first and further extracting the residue of the hexane extract with chloroform.
- the amounts of hexane and chloroform used in this extraction process are enough amounts to impregnate deer antler.
- hexane and chloroform are used in the ratio of 4-5t to 1 kg of C.N. antler.
- the chloroform extract of C.N. antler obtained from such extraction processes is fractionated and purified by a series of silica gel column chromatography and TLC (Thin layer chromatography).
- An eluent of the subsequent extracting steps is selected from chloroform/methanol, hexane/ethylacetate.
- 1-palmitoylglycerine is separated from the products in the reaction of both glycerol and palmitic acid.
- the objecting mono acetyl diacyl glycerol can be synthesized as esterifying 1-palmitoylglycerine with carboxylic acid compounds such as acetic acid and linoleic acid, and purified as occasion demands.
- Another method for synthesizing mono acetyl diacyl glycerol derivatives is the acetolysis of phosphatidyl choline.
- the mono acetyl diacyl glycerol compound according to the present invention is for immunomodulating agent.
- Immunity modulation includes increasing deteriorated immunity abnormally or maintaining the balance of increased immunity abnormally. Therefore, mono acetyl diacyl glycerol compounds according to the present invention have effects of not only preventing and treating various diseases resulted from deteriorated immune system and caner but also inhibiting, preventing, and treating autoimmune diseases such as arthritis, atopy, dementia, and sepsis resulted from autoimmune reaction.
- T cell which is responsible for immunity but the extent of T cell's activation, the ratio of T4 to T8 cells, and the kinds of cytokines secreted from T4 and T8 cells.
- the present inventors treated mono acetyl diacyl glycerol derivatives to T-4 and T-8 lymphocytes for researching the immunomodulating effect of mono acetyl diacyl glycerol derivatives of the invention. As a result, it was confirmed that secretion of IL-2, a kind of cytokines, was increased in those cells (see FIG. 1 ).
- IL-4 is a multi-function cytokine called anti-inflammation cytokine which is secreted from Th2 which is differentiated from T4 cells.
- IL-4 can suppress cell damage resulted from autoimmune reaction by processing important role to anti-cancer effect and immune response regulation (Annu. Rev. Immunol.
- the compounds of the present invention have effects of both immunity enhancing by stimulating IL-2 secretion and immunity modulating by stimulating IL-4 secretion. And, the compounds of the present invention also can maintain the ratio of T4 to T8 normally by increasing and activating not only T4 but also T8, which is a cytotoxic immune cell. Therefore, it is effective for treating on side effects and diseases resulted from abnormal increasing or decreasing of immune system. In the septic shock model, these immunity enhancing effects can work to the direction of stimulating IL-4 secretion and inhibiting apoptosis. In result, the lethal rate of sepsis is decreased remarkably. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention are useful for the treatment of autoimmune diseases, for instance the preventing and treating of sepsis, because these compounds increase IL-4 secretion.
- mono acetyl diacyl glycerol derivatives according to the present invention were confirmed to have the effects not only T-cell activation effect but also specific anti-cancer effect through activating of dendritic cells which enable T-cell to recognize antigen of cancer cells.
- mono acetyl diacyl glycerol derivatives according to the present invention were confirmed to have the immunity enhancing effect by increasing cytokine secretion through activating T-cells and by promoting the proliferation and stimulation of hematopoietic cells and immune cells through increasing the expressions of intracellular adhesion molecules.
- these compounds have the possibility of using as an immuno-therapy against various diseases.
- mono acetyl diacyl glycerol derivatives according to the present invention can be used as treatment or health food for enhancing immunity in human AIDS patients by the proliferation effect of T4 and T8 cells. In the early phase of the AIDS patients, T4 was decreased but serious outbreak did not happen.
- the present inventors investigate anti-cancer effect of the compounds against biliary cancer and malignant melanoma that were known to the incurable cancer.
- the present inventors induced cancer in a hamster by injecting intravenously or subcutaneously KIBG-5, a biliary cancer cell line.
- RPMI, BMSC, adenovirus/ ⁇ E1, dendritic cell+tumor lysate, Compound 3, adenovirus/IL-2 and the mixtures were injected to a hamster. The observation of result was performed 4 weeks later.
- tumor was formed in all groups except BMSC+adenovirus/hIL-2 treated group and BMSC+Ad/hIL-2 +Compound 3 treated group (see FIG. 10 ).
- the tumor formation was inhibited by Compound 3 dose-dependently (see FIGS. 11 and 12).
- the present inventors induced metastatic cancer in hamster by injecting biliary cancer cells (KIBG), and then treated the hamster with mono acetyl diacyl glycerol derivatives of the present invention. As a result, it was confirm that cancer development was significantly inhibited by the treatment of those compounds of the present invention.
- Intravenous injection of malignant melanoma cells was performed to the tail of mice to induce cancer therein. Then, each of or the mixture of RPMI, dendritic cells (DC), tumor lysate and Compound 3 was treated. As a result, metastatic lung lesion was formed in a control group treated with RPMI, but no lesions were observed in the groups each treated with Compound 3 and dendritic cells+tumor lysate (see FIGS. 13 and 14 ). In addition, Compound 3 treated group and dendritic cells+tumor lysate treated group were observed for 6 weeks after tumor injection, resulting in 90% survival rate (see FIG. 15 ).
- the present inventors confirmed that Compound 3 activates T-cell (T4 and 8), which means it has anti-cancer effect. So, the present inventors performed cytotoxicity test of T-cells activated by Compound 3 to malignant melanoma in vitro. As a result, cytotoxicity was increased much when T-cells were treated with Compound 3 than when T-cells were not treated with Compound 3, and also cytotoxicity was increased with the increase of the amount of T-cells (see FIG. 16 ).
- An immunomodulating agent, an AIDS treatment, a sepsis treatment, and an anti-cancer agent of the present invention preferably include mono acetyl diacyl glycerol derivatives by 20 to 100 weight % to the total weight of compounds, more preferably include them by 30 to 100 weight %. If the amount of mono acetyl diacyl glycerols is too much or less, it just difficult to take medicine and there are no advantages.
- a sepsis treatment, an anti-cancer agent, and an immunomodulating agent can be orally administered 1 to 3times/day or 1 to 4 times/day with the dose of 50 mg/kg.
- the compounds according to the present invention can additionally include one or more pharmaceutically acceptable carriers, in addition to an effective ingredient, to be formulated in a pharmaceutical form.
- the carrier can be selected from a group consisting of saline, buffered saline, water, glycerol and ethanol, but the selection is not always limited thereto. Any acceptable pharmaceutical formulation know in this field (Remingtons Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton Pa.) is available.
- a composition of the present invention can be administered orally and be used in general forms of pharmaceutical formulations.
- the composition of the present invention can be prepared for oral administration by mixing with generally used fillers, extenders, binders, wetting agents, disintegrating agents, diluents such as surfactant, or excipient.
- the effective dosage of the composition of the present invention can be determined according to age, gender, health condition, absorption of an active ingredient, inactivation rate, excretion and other medicines applied together. For example, the dosage for oral administration might be 0.24 to 9.0 g per day, but not always limited thereto.
- the present invention also includes pharmaceutical formulations in dosage units.
- the formulations are presented in the form of individual parts, for example tablets, coated tablets, capsules, pills, suppositories and ampoules, the active compound content of which corresponds to a fraction or a multiple of an individual dose.
- the dosage units can contain, for example, 1, 2, 3, or 4 individual doses or 1 ⁇ 2, 1 ⁇ 3, or 1 ⁇ 4 of an individual dose.
- An individual dose preferably contains the amount of active compound which is administered in one application and which usually corresponds to a whole, 1 ⁇ 2, 1 ⁇ 3 or 1 ⁇ 4 of a daily dose.
- Solid formulations for oral administration are tablets, pills, dusting powders and capsules
- liquid formulations for oral administration are suspensions, solutions, emulsions and syrups
- the above mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally-used simple diluents such as water and liquid paraffin.
- the compounds of the present invention can be applied not only formulations for oral administration but also formulation for injection.
- watery or oily suspension for sterile injection can be prepared according to the known method with dispersing agents, wetting agents or emulsions.
- Any acceptable pharmaceutical solvent includes water, Ringer's solution, or isotonic NaCl solution.
- Sterile fixing oil is used as solvent or dispersive medium and can include non-stimulus fixing oil including monoglyceride, diglyceride, and poly propylene glycol and fatty acid such as oleic acid.
- the present invention also provides immunomodulating and anti-cancer health food containing mono acetyl diacyl glycerol derivatives as an effective ingredient.
- health food includes foodstuff, nutrient and health supplement for treating or preventing of various diseases and maintaining the balance of body function.
- Health food prepared in the present invention contains mono acetyl diacyl glycerols by 0.02 to 100 weight %.
- the compounds of the present invention can be used according to the conventional method, for example, using intact compounds or using mixed compounds with other foods or food ingredients. The effective amount of the compound mixture depends on the purpose of its use (prevention, health or therapeutic treatment).
- the preferable amount of mono acetyl diacyl glycerol derivatives is from 0.02 to 2 weight % for the total amount of health food, preferably 0.2 to 0.6 weight %. If the amount of mono acetyl diacyl glycerols is too much or less, it just difficult to take health food and there are no advantages.
- the effective ingredient is also safe for the long-term administration aiming at the control or the preservation of health, supported by cytotoxicity test.
- Any kinds of food containing the composition of the present invention can be made without limitation. For example, meat sausage, bread, soups, beverages, teas, drinks, alcoholic beverages and vitamin complex are the food to be made as health food containing the composition of the present invention.
- the preferable amount of mono acetyl diacyl glycerol derivatives is from 20 to 100 weight % for the total amount of health food, preferably 30 to 100 weight %, more preferably 35 to 95 weight.
- the intake might be 0.18 to 9.0 g per day, but not always limited thereto.
- the formulations include tablets and capsules.
- mono acetyl diacyl glycerol derivatives of the present invention activate T-cells to promote the secretion of cytokines, increase the expression of adhesive molecules between cells to stimulate hematopoietic cells and immune cells so as to not only improve immunity but also prevent and treat autoimmune disease and cancer.
- Splenocytes were collected from C57BL/6 mice (provided from Asan Institute for Life Sciences Animal Lab., Seoul, Korea) spleens. Then, single cell suspensions were obtained by repeated aspiration and flushing. Red blood cells were removed using ammonium chloride and then passed through nylon wool to remove debris and clumps.
- T-cells were purified using magnetic bead (MACS bead, Miltenyi Biotec, bergich gladbach, Germany) containing anti-goat IgG MACS bead, Miltenyi Biotec, bergich gladbach, Germany) or anti-mouse CD4(MACS bead, Miltenyi Biotec, bergich gladbach, Germany) or anti-mouse CD8 antibody (MACS bead, Miltenyi Biotec, bergich gladbach, Germany) (Turner and Dockrell (1996) Immunology, 87: 339-342).
- T cell suspensions were suspended in Isocove's modified Dulbecco's medium (IMDM, Gibco, Grand Island, N.Y.) supplemented with 10% fetal bovine serum (referred as ‘FBS’ hereinafter) (Gibco, Grand Island, N.Y.).
- IMDM Isocove's modified Dulbecco's medium
- FBS fetal bovine serum
- 5 ⁇ 10 4 viable cells per well were cultured in 96-well plates, with 1 ⁇ g/ml of Compound 1, Compound 2, Compound 4 and Compound 5, 0.01, 0.1, 1 ⁇ g/ml of Compound 3(synthesized and provided by Department of Chemistry, Ewha Mans University, Seoul, Korea) or 20 ng/ml of IL-2.
- Monocytes were isolated from human whole blood using Histopaque 1077. And then, monocytes(5 ⁇ 10 6 cells/ml) were allowed to adhere to tissue culture flask for 3 hours in a 5% CO 2 incubator. After 3 hours, non-adherent cells were removed and adherent cells were placed in 96-well plates in RPMI 1640 medium (GIBCO, Grand Island, N.Y.) supplemented with 10% FBS. 5 ⁇ 10 4 viable cells per well were cultured in 96-well plates, with 1 ⁇ g/ml of Compound 1 ⁇ 5. On the 6 th day, cells were incubated with 1 ⁇ Ci 3 H-thymidine/well for 24 hours.
- Elispot bioassay (ESAT-6 enzyme-linked immunospot assay) is a very sensitive quantification assay for detecting cytokine bound to the membrane because the bottom of each well of Elispot plates used in this assay was pre-coated with a cytokine specific antibody. Thus, Elispot assay was performed to measure the T cell activity. T-cells were seeded by 2 ⁇ 10 6 cells to each well in a 24-well sterile tissue culture plate (Nunc, Denmark), followed by the treatment with 0.01, 0.1, 1 ⁇ g/ml concentrations of Compound 3 or IL-2 (20 ng/ml).
- Bio-plex can measure huge amount of cytokine at a time in a well.
- Bio-plex kit was used to quantify 8 kinds of cytokines of Th1/Th2 channels, which are secreted when T-cells are activated.
- Sterilized 24-well tissue culture plate (Nunc, Denmark) was treated with anti-CD3 and anti-CD28. Then, the plate was inoculated with T-cells by 2 ⁇ 10 6 cells/ml.
- 0.1, 1 ⁇ g/ml of Compound 3 was treated thereto, followed by culture for 5 days. On the 5 th day, culture solutions at each different stage were recovered, followed by centrifugation.
- cytokine secreted therein was quantified by using Bio-plex kit according to the manufacturer's instruction (Bio-rad).
- three kinds of cytokines(IL-2, IL-4, and IL-5) among 8 kinds of cytokines(IL-2, IL-4, IL-5, IL-10, IL-12, INF- ⁇ , GM-CSF, TNF- ⁇ ) were secreted in the group treated with Compound 3 and the amounts of them were bigger than those in a control group not treated with Compound 3 ( FIG. 2 ).
- Bone marrow cells were obtained from the femurs and tibias of Balb/c AnN mice (Park, J. et al. (2003) J. Korean Med. Sci., 18: 372-380). The cells were washed 3 times in RPMI, and then mononuclear cells were obtained. These mononuclear cells were allowed to adhere to tissue culture flask 3 hours in RPMI and 10% FBS.
- the adherent cells(monocytes) were removed and non-adherent cells were placed in 100 mm tissue culture dishes, in a concentration of 1 ⁇ 10 5 cells/ml in RPMI plus 10% FBS supplemented with 20 ng/ml murine rGM-CSF(R&D systems, Minneapolis, Minn., USA), 10 ng/ml, murine IL-4(R&D systems), and 2.5 ng/m1 murine TNF- ⁇ (R&D systems).
- Culture dishes were fed every 3 days.
- Murine TNF- ⁇ (R&D systems) was added at the 6 th day of the culture. After that, murine TNF- ⁇ (R&D systems) was added every 3 days until on the 11th day.
- Mature dendritic cells were harvested for RT-PCR of adhesion molecule studies. As a result, when round shaped granulocytes were cultured for three days, those cells formed a cluster which was growing on the bottom of a well of cell culture plate, and mature dendritic cells were growing with forming a group on the 6 th or the 7 th day of culture. And on the 9 th day of culture, dendritic cells formed a small but long protrusion specifically ( FIG. 3 ).
- Flow cytometric analysis of the fixed cells was performed by using FACScan (Beckton Dickinson, Mountain View, Calif., U.S.A), leading to the determination of the phenotype using antibodies against the following markers; isotype control against hamster IgG, rat IgG 2a, DC marker: DEC 205(NLDC-145) and CD 11C, co-stimulatory/adhesion molecule: CD 80(B7-1) and CD 86(B7-2), macrophage marker: CD 14 and F4/80, granulocyte marker: Gr-1 (Pharmingen, Hamburg, Germany).
- the levels of co-stimulation specific molecular markers CD80 and C86 and dendritic cell specific markers CD11C and DEC-205 were high.
- the levels of monocytes specific markers CD14 and F4/80 and granulocyte specific marker Gr-1 were low.
- the results indicate that the dendritic cells separated in the present invention have an exact phenotype of dendritic cells and the purity 97 to 98% ( FIG. 4 ).
- Icam-1 (SEQ. ID. No 1 and No 2), Icam-2(SEQ. ID. No 3 and No 4), Vcam-1(SEQ. ID. No 5 and No 6), VLA-4(SEQ. ID. No 7 and No 8), VLA-5(SEQ. ID. No 9 and No 10), LFA-1(SEQ. ID. No 11 and No 12) and GAPDH(SEQ. ID. No 13 and No 14) were used for the RT-PCR.
- Reaction sets used herein was a mixed solution of 2 ⁇ l DNA, 10 ⁇ buffer solution, 1.5 ⁇ l of MgCl 2 , 2 ⁇ l of dNTPs, 0.5 ⁇ l of forward primer, 0.5 ⁇ l of reverse primer, 0.2 ⁇ l of polymerase and 15.8 ⁇ l of distilled water.
- adhesion molecules such as Vcam-1, Icam-1, Icam-2, VLA-4, VLA-5, and LFA-1 were confirmed by RT-PCR.
- PCR with GAPDH was performed to confirm the corresponding cDNA. The results showed that the expressions of adhesion molecules, Icam-2, VLA-5, LFA-1 on Compound 3 treated dendritic cells were significantly increased compared to a control ( FIG. 5 ).
- KIBG-5 cells Molecular therapy , Vol. 3, No. 4, pp431-437
- RPMI 1640 serum-free medium were intravenously injected via femoral vein.
- 5 ⁇ 10 5 KIBG-5 cells suspended in 100a of RPMI 1640 serum-free medium were subcutaneously injected to the flank of the hamsters.
- Hamsters injected KIBG-5 were divided into following 7 groups;
- BMSC treated group One week after the injection of cancer cells to hamsters (BMSC treated group), 2.5 ⁇ 10 6 of BMSC cells were injected once again to each hamster.
- DC+tumor lysate treated group 5 ⁇ 10 6 of DC cells and tumor lysate were injected to each hamster (with subcutaneous injection or intravenous injection) at the first, second, third, forth, sixth, eighth week, followed by observation for 12 weeks.
- Compound 3 treated group one week before KIBG-5 cells injection, Compound 3(25 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 8 weeks.
- KIGB-5 cells (5 ⁇ 10 5 ) suspended in 1000, of RPMI 1640 serum-free medium were intravenously injected via femoral vein.
- Hamsters were divided into following 4 groups: 1) PBS control group, 2) Compound 3 (10 mg/kg/day) treated group, 3) Compound 3 (25 mg/kg/day) treated group, 4) Compound 3 (50 mg/kg/day) treated group.
- One week before tumor cell injection Compound 3 (10, 25 or 50 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 12 weeks. Animals of each group were sacrificed at 4, 8, 12 weeks for pathological examination.
- B16F10 cells (2 ⁇ 10 4 ) suspended in 100 ⁇ l of RPMI 1640 serum-free medium were intravenously injected via tail vein. One week before tumor cell injection, the following 3 groups were treated.
- DC+tumor lysate treated group In the case of DC+tumor lysate treated group, one week before melanoma injection, 5 ⁇ 10 5 DC cells mixed with tumor lysate were injected to the abdominal cavity every 1 weeks. In the case of Compound 3 treated group, 50 mg/kg/day of Compound 3 was treated to each mouse. One week before melanoma(B16F10) injection, Compound 3(50 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 6 weeks. As a result, gross findings at 4 th week control group observed multiple metastatic lesions in both lungs. Compound 3 treated group and DC +tumor lysate treated group showed no evidence of disease in the lung ( FIG. 13 , 14 ) and showed 90% survival rate in the observation for 6 weeks after melanoma (B16F10) injection ( FIG. 15 ).
- cytotoxicity of T-cells activated by Compound 3 to malignant melanoma cells was investigated. As a result, when the ratio of T-cells activated by Compound 3 to melanoma cells was 100:1, cytotoxicity was 42% increased( FIG. 16 ).
- Synthesized Compound 3 was dissolved in 5% ethanol solution which was orally administered at the 0.1 ml/20 g dose. Control group was treated 5% ethanol solution.
- IRC mice housed in SPF facility were used as test animals. The animals were fasted for one day before drug administration, and had free access to water and chow thereafter. Eight to ten ICR mice, 25-35 g of weight, were grouped. The test agent was orally administered once at increasing doses ranging from 62.5 mg/kg, 125 mg/kg, 250 mg/kgkg, 500 mg/kg, 1.0 g/kg, to 2.0 g/kg. From the day of administration, survival number and any abnormal signs were observed with the naked eye for 14 days. LD 50 was calculated by the method of Lichfield-Wilcoxon ( -
- Weight increment rate(%) ⁇ Weight of day 14—Weight of day 0 ⁇ ⁇ Weight of day 0 ⁇ 100 [Mathematical Formula 2]
- CLP test was performed in order to confirm the effect of Compound 3 for prevention and treatment against septic shock.
- Ten 7-10 week old male inbred C3H/HeN mice(20-25 g of weight) were grouped. After 50 mg/kg/day of Compound 3 was orally administered to mice for 2 weeks on and 1 week off, mice were anesthetized with 80 mg/kg of ketamine and 16 mg/kg of rompun.
- Septic shock was induced by CLP model in anesthetized mice. One hour after inducing septic shock, 50 mg/kg of Compound 3 was treated, and then, the same treatment was continued for 3 days every 24 hours.
- Control group was orally administered PBS+5% ethanol solution. Survival rate of Compound 3 treated group and control group with time lapse was shown in Table 6. Compound 3 treated groups had 100% survival rate even after lapse of 120 hours.
- the present inventors prepared a treatment containing Compound 3 as an effective ingredient. Further, the followed manufacturing example of the treatment containing Compound 3 as an effective ingredient can be applied not only to the preparing of treatment but also to the preparing of health food. If there isn't extra mention, the symbol of % means weight % in the following manufacturing example.
- Vitamin C 30% Vitamin C 4.5% Vitamin D3 0.001% Manganese sulfate 0.1% Wax 10% Palm oil 25% Safflower oil ( Carthamus tinctorius ) 30.399%
- Vitamin E acetate ester (DL- ⁇ -tocopherol acetate) 2.0%
- Vitamin C 10% Vitamin D3 0.001% Manganese sulfate 0.1% Crystalline cellulose 25.0% Lactose 32.999% Magnesium Stearate 2%
- the injection formulation was prepared by the conventional method with above mentioned compositions and contents.
- Soft gelatin capsules, tablets and injection suspension were prepared by the same method and composition as described in the above manufacturing example 1, except the Compound 3 was substituted with Compound 1, 2, 4, and 5 at the same ratio.
- the present inventors prepared health food containing the same as an effective ingredient.
- Beverage was prepared based on the above compositions and contents by following a conventional method.
- Chewing gum was prepared based on the above compositions and contents by following a conventional method.
- Biscuit was prepared based on the above compositions and contents by following a conventional method.
- Ice cream was prepared based on the above compositions and contents by following a conventional method.
- Beverage, chewing gum, candy, biscuit, ice cream and chocolate were prepared by the same method and composition as described in the above manufacturing example 3, except the Compound 3 was substituted with Compound 1, 2, 4, and 5 at the same ratio.
- the mono acetyl diacyl glycerol derivatives containing Compound 3 shows significant effect for immuno modulation including immune enhancing.
- cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell.
- mouse induced septic shock it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.
Abstract
The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.
Description
- This application is a divisional of U.S. application Ser. No. 11/587,377, filed Jul. 31, 2007, which is a US National stage entry of International Application No. PCT/KR2005/001175, which designated the United States and was filed on Apr. 22, 2005, published in English. This application claims priority under 35 U.S.C. §119 or 365 to Korean Application No. 10-2004-0028514, filed Apr. 24, 2004, Korean Application No. 10-2004-0070650, filed Sep. 4, 2004 and Korean Application No. 10-2004-0109805, filed Dec. 21, 2004. The entire teachings of the above applications are incorporated herein by reference.
- This invention relates to uses of immunomodulating agent, medical supplies, and health foods containing mono acetyl diacyl glycerol derivatives extracted from deer antler as an effective ingredient.
- Antler (in Latin, Cervi parvum cornu) is an uncalcified horn harvested and dried from any animal of the deer family. In traditional oriental medicine in Korea, deer antlers together with ginseng have been widely used for their various acclaimed medicinal effects. The deer family for the traditional use of antlers are limited only Cervus nippon Temminick var. mantchuricus Swinhoe (Referred as C.N. hereafter) and Cervus elaphus L. Deer antler has been acclaimed to have numerous medicinal effects. It has been known to be efficacious in tonic agents, growth and development promotion, hematopoiesis, treating nervous breakdown, treating cardiac insufficiency, and generally improving the function of the five viscera and six entrails (Dong-euibogam, a classical medical literature in Korea). Other literatures in traditional medicine, concerning the effects of deer antlers, also reported that tonic effects, nourishing effect, strengthening vitality effects including improving cardiac function, relieving fatigue effects, enhancing immunity. Many attempts have been made to uncover the curious chemical make-up of antler. As a result, it is found to contain active gradients such as free amino acids, trace (metallic) elements, hexose, pentose, hexosamine, uronic acid, sialic acid, mucopolysaccharides (e.g. hyaluronic acid, chondroitin A), various fatty acids, prostaglandins. It has also been reported that glycolipid, phospholipid, cholesterol, hypoxanthine, cholest-5-ene-3β,7α-diol, cholesterol ester, polyamine were detected in the extracts from deer antler. Others reported the presence of estrone, and estradiol receptor (report of NIH Korea, Vol.22, p359, 1985; Korean Biochem. J, Vol.9, No.3, p153, 1976; Korean Biochem. J, Vol.9, No.4; p215, 1976; Korean Biochem. J, Vol.10, No.1, pl, 1977; Shoykugaku Zasshi, 43(2), p173, 1989).
- Immunity is a defense mechanism protecting a living body from various pathogens. Immunodeficiency is resulted from a defect in a constituent of immune system, indicating that immune system is unable to response to various antigens. Immunodeficiency is largely divided into congenital or primary immunodeficiency and acquired or secondary immunodeficiency. In the case of congenital immunodeficiency, B-cells or T-cells do not exist naturally, so it can be treated only by gene therapy, antibody insertion and bone marrow transplantation. On the other hand, in the case of acquired immunodeficiency, all the immune related factors exist naturally but there is malfunctioning in immune response, so it can be improved by promoting the functions of immune factors. Recently the outbreak of autoimmune diseases such as arthritis, atopy, dementia and sepsis have been increased. Autoimmune diseases are resulted from over increasing of immune function. An immune suppressor has been used to remedy autoimmune diseases, but the immune suppressor also causes decreasing of immunity frequently. Based on the disclosure of immune mechanism, various attempts have been made to develop an immune regulator for the control of immunity. The purpose of these attempts is for increasing defensive power of a living body against pathogens and minimizing side-effects by controlling promotion or suppression of immune function with immune regulators which can stimulate immune cells non-specifically. Immune regulators can remedy almost diseases of living body such as cancer, sepsis, degenerative arthritis, infection, dementia, aging, diabetes, anemia, skin disease, asthma, atopy, stress, nerve breakdown, physical fatigue, chronic fatigue syndrome, and osteoporosis. As of today, chemical compounds, microorganism compositions, biological products, etc, have been used as an immune regulator. Most of those immune regulators are limited in using because they are inclined to work only one effect (either immune promotion or suppression). Therefore, they may cause side effects and have toxicity themselves. In order to overcome above mentioned problems, foodstuffs without toxicity, effective ingredients extracted from natural sources and the traditional herb medicines are the major targets to develop immune regulators and experiments to examine their effects as a medicine have been on trial. But these immune regulators still have either immune promotion or suppression effect.
- Cancer, the leading cause of death in Korea, has been increasing every year. Chemo-therapy or radio-therapy for the treatment of cancer not only kills cancer cells but also destroys normal bone marrow cells, especially hematopoietic cells regulating immunity and hematopoieses, resulting in the malfunction of immune system and hematopoietic organ (Korean J. BRM., 1, p23, 1993; Korean J. BRM., 4, p47, 1994; Crit Rev Oncol Hematol. 1, p227, 1984). Sepsis is a serious disease having over 45% lethal rate caused by a severe systemic infection leading to a systemic inflammatory response. It almost happens when infected hosts response excessively against endotoxin from gram negative bacteria. However Antibiotics, steroid, or Xigris (Eli Lilly company) have been used as a septic shock treatment, the lethal rate from septic shock is still high because theses antibiotics, steroid, or Xigris are ineffective against sepsis.
- Thus, the present inventors separated various ingredients of C.N. antler which has been known to having excellent pharmaceutical effects as a folk remedy, and further observed that one of those effective ingredients of C.N. antler, mono acetyl diacyl glycerol, showed significant immune regulation activity in vivo. As a result of immune regulation effects, the C.N. antler has a possibility of using for septic shock treatment and anti-cancer agent without causing toxicity in vivo. And, the present inventors completed this invention by confirming that mono acetyl diacyl glycerol of the invention can be used as a safe immune enhancing agent, an immunomodulating agent, a septic shock treatment and an anti-cancer agent.
- Therefore, it is an object of the present invention to provide an immunomodulating agent, a septic shock treatment, an anti-cancer agent, and health foods containing mono acetyl diacyl glycerol derivatives as an effective ingredient. Health foods are for modulating immune, preventing or treating septic shock and cancer.
- In order to achieve the above object, the present invention provides an immunomodulating agent containing mono acetyl diacyl glycerol derivatives represented by the following
formula 1 as an effective ingredient. - wherein, R1/R2 is 9-octadecenoyl(oleoyl)/hexadecanoyl(palmitoyl), hexadecanoyl (palmitoyl)/(9-octadecenoyl(oleoyl), hexadecanoyl(palmitoyl)/9,12-octadecadienoyl(linoleoyl), hexadecanoyl(palmitoy1)/9,12,15-octadecatrienoyl (linolenoyl) or hexadecanoyl(palmitoyl)/5,8,11,14-eicosatetraenoyl(arachidonoyl).
- Here, above mentioned mono acetyl diacyl glycerol derivatives represented by the
below formula 2 is preferred. - The present invention also provides an AIDS treatment, a sepsis treatment, and an anti-cancer agent containing mono acetyl diacyl glycerol derivatives of
formula 1 as an effective ingredient. The present invention further provides health foods containing mono acetyl diacyl glycerol derivatives offormula 1 as an effective ingredient for an immune modulation or the prevention of cancer. - The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.
-
FIG. 1 is a set of photographs showing the T-cell (T-4 and T-8) activity of control group, IL-2 treated group (20 ng/ml), and Compound 3 treated group (1 μg/ml). Each number indicates the number of spots capturing IL-2 specific antibody. -
FIG. 2 is a graph showing the release of cytokines when T lymphocytes are activated by Compound 3, - 1. Control group: anti-CD3, anti-CD28 treated,
- 2. Experimental group: anti-CD3, anti-CD28 and Compound 3(0.1, 1 μg/ml) treated.
-
FIG. 3 is a set of photographs showing the morphology of mouse dendritic cells derived from mouse bone marrow cells after the treatment of GM-CSF (20ng/m1), IL-4(20 ng/ml) and TNF-α (5 ng/ml). - A: a microscopic photograph taken right after the inoculation of mouse bone marrow cells with the density of 1×106 cells/ml (×100).
- B: a microscopic photograph showing the round bone marrow stem cells after three days culture. Those cells formed a cluster, which was growing on the bottom of a well of a cell culture plate (×400).
- C: a microscopic photograph of the growing mature dendritic cells which are forming cluster on the 6th day or 7th day of culture (×400), the small photograph is the enlarged photograph of the specific cell (×2).
- D: a microscopic photograph of the dendritic cells which are forming specific small and long protrusions on the 9th day of culture (×1000), the small photograph is the enlarged photograph of the specific cell (×2).
-
FIG. 4 is a set of graphs showing the results of FACS analyzing the expressions of the dendritic cell specific markers, a monocyte specific marker and a granulocyte specific marker on the 11th day of culture of bone marrow cells separated from Balb/c AnN mouse. (Here, staining of isomer control against hamster's IgG and rat's IgG2a is used for a setting marker line (straight line). - Following markers are used:
- CD80 and CD86 as co-stimulation specific markers,
- CD11c and DEC-205 as dendritic cell specific markers,
- CD14 and F4/80 as monocyte/macrophage specific markers,
- Gr-1 as a granulocyte specific marker.
-
FIG. 5 is an electrophoresis photograph showing the effects ofCompound 3 on dendritic cells on the expression of adhesion molecules. -
Lane 1: Vcam-1 Lane 2: Icam-1 Lane 3: Icam-2 Lane 4: VLA-4 Lane 5: VLA-5 Lane 6: LFA-1 Lane 7: GAPDH (+): Compound 3 treated group(−): Control group. -
FIG. 6 is a set of photographs showing the results of tumor forming at the near injection site, 4 weeks after tumor (KIGB-5) i.v. injection and processing with different condition. - A: RPMI control group B: BMSC treated group
- C: BMSC Ad/AE1 treated group.
-
FIG. 7 is a set of photographs showing the results of tumor forming at the near injection site, 8 weeks after tumor (KIGB-5) i.v. injection and processing with different condition. - A: RPMI control group
- B: BMSC(2.5×106 cells/day) treated group
- C: BMSC(2.5×106 cells/day)+Ad/ΔE1(50 MOI) treated group
- D: Dendritic Cells(5×106 cells/day)+Tumor lysate treated group
- E: BMSC(2.5×106 cells/day)+Ad/IL-2(50 MOI) treated group
- F: Compound 3 (50 mg/kg/day) treated group.
-
FIGS. 8 and 9 are a set of photographs showing the gross and microscopic findings of metastatic lung lesions of each group, 8 weeks after tumor (KIGB-5) i.v. injection. - In
FIG. 8 , - A: RPMI control group
- B: BMSC(2.5×106 cells/day) treated group
- C: BMSC(2.5×106 cells/day)+Ad/ΔE 1 (50 MOI) treated group
- D: BMSC(2.5×106 cells/day)+Ad/IL-2(50 MOI) treated group.
- In
FIG. 9 , - A: RPMI control group
- B: Dendritic Cells(5×106 cells/day)+Tumor lysate treated group
- C: Compound 3 (25 mg/kg/day) treated group.
-
FIG. 10 is a set of photographs showing the lung tumors and its size of each group, 12 weeks after tumor (KIGB-5) s.c(subcutaneously) injection. - A: RPMI control group
- B: BMSC(2.5×106 cells/day)+Ad/ΔE1 (50 MOI) treated group
- C: BMSC(2.5×106 cells/day) treated group
- D: DC(5×106 cells/day)+Tumor lysate treated group
- E: BMSC(2.5×106 cells/day)+Ad/IL-2(50 MOI) treated group
- F: BMSC(2.5×106 cells/day)+Ad/IL-2(50 MOI)+Compound 3 (25 mg/kg/day) treated group
- G: Compound 3 (25 mg/kg/day) treated group.
-
FIG. 11 is a set of photographs showing gross findings of metastatic lung lesions of each group of Syrian golden hamsters treated with various doses ofCompound - A: PBS Control group
- B: Compound 3 (10 mg/kg/day) treated group
- C: Compound 3 (25 mg/kg/day) treated group
- D: Compound 3 (50 mg/kg/day) treated group
-
FIG. 12 is a set of photographs showing microscopic findings of metastatic lung lesions of each group of Syrian golden hamsters treated with various doses ofCompound - A: PBS Control group
- B: Compound 3 (10 mg/kg/day) treated group
- C: Compound 3 (25 mg/kg/day) treated group
- D: Compound 3 (50mg/kg/day) treated group
-
FIG. 13 is a set of photographs showing gross findings of metastatic lung lesions of each of C57B1/6 mice received various treatments, 4 weeks after melanoma cells (2×104 cells) i.v. injection. - A: PBS Control group
- B: Dendritic cells (4×105 cells/day)+tumor lysate treated group
- C: Compound 3 (50 mg/kg/day) treated group.
-
FIG. 14 is a set of photographs showing microscopic findings of metastatic lung lesions of each of C57B1/6 mice received various treatments, 4 weeks after melanoma cells (2×104 cells) i.v. injection. - A: PBS Control group
- B: Dendritic cells (4×105 cells/day)+tumor lysate treated group
- C: Compound 3 (50 mg/kg/day) treated group.
-
FIG. 15 is a graph showing survival rate of each treated group during 6 weeks after melanoma cells. (2×104 cells) i.v. injection. - 1. RPMI control group
- 2. Dendritic cells (5×105 cells/day)+tumor lysate treated group
- 3. Compound 3 (50 mg/kg/day) treated group.
- FIG.16 is a graph showing the cytotoxicity of T lymphocytes activated by
Compound 3 on melanoma cells. - 1. Control 1: anti-CD3, anti-CD28 treated group
- 2. Control 2: anti-CD3, anti-CD28, and IL-2 (20 ng/ml) treated group
- 3. Experimental group: anti-CD3, anti-CD28, and Compound 3(1 μg/ml) treated group.
- A description of preferred embodiments of the invention follows. The present invention provides an immunomodulating agent, an AIDS treatment, a sepsis treatment, and an anti-cancer agent containing mono acetyl diacyl glycerol derivatives represented by the following
formula 1 as an effective ingredient. The compound represented byformula 1 of the present invention is one of following 5 compounds: - 1) 1-oleoyl-2-2palmitoyl-3-acetylglycerol(R1/R2=9-octadecenoyl/hexadeca noyl, referred as “
Compound 1” hereinafter) - 2) 1-palmitoyl-2-oleoyl-3-acetylglycerol(R1/R2=hexadecanoyl-octadece noyl, referred as “
Compound 2” hereinafter) - 3) 1-palmitoyl-2-linoleyl-3-acetylglycerol(R1/R2=hexadecanoyl/9,12-octa decadienoyl, referred as “
Compound 3” hereinafter) - 4) 1-palmitoyl-2-linolenoyl-3-acetylglycerol(R1/R2=hexadecanoyl9,12,15-octadecatrienoyl, referred as “Compound 4” hereinafter)
- 5) 1-palmitoyl-2-arachidonoyl-3-acetylglycerol(R1/R2=hexadecanoyl/5,8,11, 14-eicosatetraenoyl, referred as “Compound 5” hereinafter).
- Any of mono acetyl diacyl glycerol derivative represented by
formula 2 is available and in particular,Compound 3 is preferred. The compound of the present invention was extracted from C.N. antlers or manufactured by conventional organic synthesis method. The exemplary of extraction method has the following steps. Particularly, the chloroform extracts of C.N. antler are obtained by extracting C.N. antler with hexane first and further extracting the residue of the hexane extract with chloroform. The amounts of hexane and chloroform used in this extraction process are enough amounts to impregnate deer antler. Generally, hexane and chloroform are used in the ratio of 4-5t to 1 kg of C.N. antler. The chloroform extract of C.N. antler obtained from such extraction processes, is fractionated and purified by a series of silica gel column chromatography and TLC (Thin layer chromatography). An eluent of the subsequent extracting steps is selected from chloroform/methanol, hexane/ethylacetate. In order to synthesize mono acetyl diacyl glycerol derivatives chemically, for instance, 1-palmitoylglycerine is separated from the products in the reaction of both glycerol and palmitic acid. The objecting mono acetyl diacyl glycerol can be synthesized as esterifying 1-palmitoylglycerine with carboxylic acid compounds such as acetic acid and linoleic acid, and purified as occasion demands. Another method for synthesizing mono acetyl diacyl glycerol derivatives is the acetolysis of phosphatidyl choline. - The mono acetyl diacyl glycerol compound according to the present invention is for immunomodulating agent. Immunity modulation includes increasing deteriorated immunity abnormally or maintaining the balance of increased immunity abnormally. Therefore, mono acetyl diacyl glycerol compounds according to the present invention have effects of not only preventing and treating various diseases resulted from deteriorated immune system and caner but also inhibiting, preventing, and treating autoimmune diseases such as arthritis, atopy, dementia, and sepsis resulted from autoimmune reaction.
- In the regulation of immune function, the important thing is not increase of T cell which is responsible for immunity but the extent of T cell's activation, the ratio of T4 to T8 cells, and the kinds of cytokines secreted from T4 and T8 cells. The present inventors treated mono acetyl diacyl glycerol derivatives to T-4 and T-8 lymphocytes for researching the immunomodulating effect of mono acetyl diacyl glycerol derivatives of the invention. As a result, it was confirmed that secretion of IL-2, a kind of cytokines, was increased in those cells (see
FIG. 1 ). After treating the cells with theCompound 3 of the present invention by using Bio-plex, which enables measuring huge amount of cytokines at a time, the secretion of cytokine in T-cells was investigated. As a result, the secretions of IL-2, IL-4, and IL-5 were much greater inCompound 3 treated group than in a control group (seeFIG. 2 ). The most increased cytokine, IL-4 is a multi-function cytokine called anti-inflammation cytokine which is secreted from Th2 which is differentiated from T4 cells. As inhibiting differentiation of T4 to Th1, IL-4 can suppress cell damage resulted from autoimmune reaction by processing important role to anti-cancer effect and immune response regulation (Annu. Rev. Immunol. 1999. 17: 701-738). The compounds of the present invention have effects of both immunity enhancing by stimulating IL-2 secretion and immunity modulating by stimulating IL-4 secretion. And, the compounds of the present invention also can maintain the ratio of T4 to T8 normally by increasing and activating not only T4 but also T8, which is a cytotoxic immune cell. Therefore, it is effective for treating on side effects and diseases resulted from abnormal increasing or decreasing of immune system. In the septic shock model, these immunity enhancing effects can work to the direction of stimulating IL-4 secretion and inhibiting apoptosis. In result, the lethal rate of sepsis is decreased remarkably. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention are useful for the treatment of autoimmune diseases, for instance the preventing and treating of sepsis, because these compounds increase IL-4 secretion. - It has been known to that the interaction between cells stimulate various hematopoietic cells and immune cells, and particularly, dendritic cells are very important in immune system. The present inventors investigated the effect of mono acetyl diacyl glycerol derivatives on the interaction between separated and induced dendritic cells and TCR (T-cell Receptor). For the investigation, RT-PCR of the
Compound 3 treated DC (Dendritic Cells) was performed to measure the expressions of adhesion molecules mediating the interaction between DC and TCR. As a result, the expression of adhesive molecules such as Vcam-1, Icam-1, Icam-2, VLA-4, VLA-5, and LFA-1 were increased, comparing to a control (seeFIG. 5 ). From the above results, mono acetyl diacyl glycerol derivatives according to the present invention were confirmed to have the effects not only T-cell activation effect but also specific anti-cancer effect through activating of dendritic cells which enable T-cell to recognize antigen of cancer cells. - From the above results, mono acetyl diacyl glycerol derivatives according to the present invention were confirmed to have the immunity enhancing effect by increasing cytokine secretion through activating T-cells and by promoting the proliferation and stimulation of hematopoietic cells and immune cells through increasing the expressions of intracellular adhesion molecules. As a result, it was confirmed that these compounds have the possibility of using as an immuno-therapy against various diseases. For instance, mono acetyl diacyl glycerol derivatives according to the present invention can be used as treatment or health food for enhancing immunity in human AIDS patients by the proliferation effect of T4 and T8 cells. In the early phase of the AIDS patients, T4 was decreased but serious outbreak did not happen. On the other hand, in the late phase of the AIDS patient, T8 was decreased and serious outbreak happened. Therefore, the ratio of T4 to T8 is an important factor and the absolute number of T4 and T8 is also an important factor. Further, the present inventors confirmed that the modulation of immune function by the increasing of the IL-4 secretion is effective for various autoimmune diseases. In order to investigate the use of compounds according to the present invention as prevention and treatment for septic shock, the CLP (Cecal Ligation and Puncture) test of mice was performed. In result, all tested mice survived until 120 hours. Therefore, it confirmed that mono acetyl diacyl glycerol derivatives according to the present invention were effective for preventing and treating of sepsis. From the above results, it confirmed that mono acetyl diacyl glycerol derivatives according to the present invention were good for ideal immunomodulating agent having both immunity enhancing effect and immunity function regulation effect.
- Further, in order to investigate the use of compounds according to the present invention for prevention and treatment of cancer, the present inventors investigate anti-cancer effect of the compounds against biliary cancer and malignant melanoma that were known to the incurable cancer. First, the present inventors induced cancer in a hamster by injecting intravenously or subcutaneously KIBG-5, a biliary cancer cell line. Then, RPMI, BMSC, adenovirus/ΔE1, dendritic cell+tumor lysate,
Compound 3, adenovirus/IL-2 and the mixtures were injected to a hamster. The observation of result was performed 4 weeks later. As a result, when it observed by the naked eye or a microscope, dendritic cell+tumor lysate,Compound 3, and adenovirus/IL-2 treated groups did not form tumor (seeFIG. 6 ). Further, tumor cells were injected intravenously and observation was performed 8 weeks later. As a result, metastatic lung lesion was formed in all groups except BMSC+adenovirus/IL-2 treated group. From the biopsy, only a minute lesion was observed in dendritic cell+tumor lysate treated group andCompound 3 treated group (seeFIG. 7 ,FIG. 8 , andFIG. 9 ). And further, tumor cells were injected subcutaneously and observation was performed 12 weeks later. As a result, tumor was formed in all groups except BMSC+adenovirus/hIL-2 treated group and BMSC+Ad/hIL-2+Compound 3 treated group (seeFIG. 10 ). The tumor formation was inhibited byCompound 3 dose-dependently (see FIGS. 11 and 12). As explained hereinbefore, the present inventors induced metastatic cancer in hamster by injecting biliary cancer cells (KIBG), and then treated the hamster with mono acetyl diacyl glycerol derivatives of the present invention. As a result, it was confirm that cancer development was significantly inhibited by the treatment of those compounds of the present invention. - Intravenous injection of malignant melanoma cells was performed to the tail of mice to induce cancer therein. Then, each of or the mixture of RPMI, dendritic cells (DC), tumor lysate and
Compound 3 was treated. As a result, metastatic lung lesion was formed in a control group treated with RPMI, but no lesions were observed in the groups each treated withCompound 3 and dendritic cells+tumor lysate (seeFIGS. 13 and 14 ). In addition,Compound 3 treated group and dendritic cells+tumor lysate treated group were observed for 6 weeks after tumor injection, resulting in 90% survival rate (seeFIG. 15 ). Based on the above results, the present inventors confirmed thatCompound 3 activates T-cell (T4 and 8), which means it has anti-cancer effect. So, the present inventors performed cytotoxicity test of T-cells activated byCompound 3 to malignant melanoma in vitro. As a result, cytotoxicity was increased much when T-cells were treated withCompound 3 than when T-cells were not treated withCompound 3, and also cytotoxicity was increased with the increase of the amount of T-cells (seeFIG. 16 ). As explained hereinbefore, it was confirmed that mono acetyl diacyl glycerol derivatives of the present invention inhibit cancer development and show cytotoxicity to cancer cells by activating T-cells, indicating that the compounds of the present invention can be effectively used as an anti-cancer agent. The treatment with the product of the present invention as an anti-cancer agent appears to be promising for bile duct cancer, kidney cancer and melanoma, but other forms of malignant diseases should be explored. - The present inventor, henceforth, completed this invention by preparing trial capsules and tablets containing mono acetyl diacyl glycerol derivatives as an effective ingredient. An immunomodulating agent, an AIDS treatment, a sepsis treatment, and an anti-cancer agent of the present invention preferably include mono acetyl diacyl glycerol derivatives by 20 to 100 weight % to the total weight of compounds, more preferably include them by 30 to 100 weight %. If the amount of mono acetyl diacyl glycerols is too much or less, it just difficult to take medicine and there are no advantages. It is also preferred for a sepsis treatment, an anti-cancer agent, and an immunomodulating agent to be orally administered 1 to 3times/day or 1 to 4 times/day with the dose of 50 mg/kg. The compounds according to the present invention can additionally include one or more pharmaceutically acceptable carriers, in addition to an effective ingredient, to be formulated in a pharmaceutical form. The carrier can be selected from a group consisting of saline, buffered saline, water, glycerol and ethanol, but the selection is not always limited thereto. Any acceptable pharmaceutical formulation know in this field (Remingtons Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton Pa.) is available. A composition of the present invention can be administered orally and be used in general forms of pharmaceutical formulations. The composition of the present invention can be prepared for oral administration by mixing with generally used fillers, extenders, binders, wetting agents, disintegrating agents, diluents such as surfactant, or excipient. The effective dosage of the composition of the present invention can be determined according to age, gender, health condition, absorption of an active ingredient, inactivation rate, excretion and other medicines applied together. For example, the dosage for oral administration might be 0.24 to 9.0 g per day, but not always limited thereto. The present invention also includes pharmaceutical formulations in dosage units. This means that the formulations are presented in the form of individual parts, for example tablets, coated tablets, capsules, pills, suppositories and ampoules, the active compound content of which corresponds to a fraction or a multiple of an individual dose. The dosage units can contain, for example, 1, 2, 3, or 4 individual doses or ½, ⅓, or ¼ of an individual dose. An individual dose preferably contains the amount of active compound which is administered in one application and which usually corresponds to a whole, ½, ⅓ or ¼ of a daily dose. Solid formulations for oral administration are tablets, pills, dusting powders and capsules, liquid formulations for oral administration are suspensions, solutions, emulsions and syrups, and the above mentioned formulations can contain various excipients such as wetting agents, sweeteners, aromatics and preservatives in addition to generally-used simple diluents such as water and liquid paraffin. The compounds of the present invention can be applied not only formulations for oral administration but also formulation for injection. For example, watery or oily suspension for sterile injection can be prepared according to the known method with dispersing agents, wetting agents or emulsions. Any acceptable pharmaceutical solvent includes water, Ringer's solution, or isotonic NaCl solution. Sterile fixing oil is used as solvent or dispersive medium and can include non-stimulus fixing oil including monoglyceride, diglyceride, and poly propylene glycol and fatty acid such as oleic acid.
- The present invention also provides immunomodulating and anti-cancer health food containing mono acetyl diacyl glycerol derivatives as an effective ingredient. In the present invention, “health food” includes foodstuff, nutrient and health supplement for treating or preventing of various diseases and maintaining the balance of body function. Health food prepared in the present invention contains mono acetyl diacyl glycerols by 0.02 to 100 weight %. In the case of using the compounds of the present invention as health food, the compounds can be used according to the conventional method, for example, using intact compounds or using mixed compounds with other foods or food ingredients. The effective amount of the compound mixture depends on the purpose of its use (prevention, health or therapeutic treatment). In the case of using for prevention, the preferable amount of mono acetyl diacyl glycerol derivatives is from 0.02 to 2 weight % for the total amount of health food, preferably 0.2 to 0.6 weight %. If the amount of mono acetyl diacyl glycerols is too much or less, it just difficult to take health food and there are no advantages. The effective ingredient is also safe for the long-term administration aiming at the control or the preservation of health, supported by cytotoxicity test. Any kinds of food containing the composition of the present invention can be made without limitation. For example, meat sausage, bread, soups, beverages, teas, drinks, alcoholic beverages and vitamin complex are the food to be made as health food containing the composition of the present invention. In case that the health food is used as nutrients or health supplements for the purpose of treating and preventing disease, the preferable amount of mono acetyl diacyl glycerol derivatives is from 20 to 100 weight % for the total amount of health food, preferably 30 to 100 weight %, more preferably 35 to 95 weight. The intake might be 0.18 to 9.0 g per day, but not always limited thereto. The formulations include tablets and capsules.
- As explained hereinbefore, mono acetyl diacyl glycerol derivatives of the present invention activate T-cells to promote the secretion of cytokines, increase the expression of adhesive molecules between cells to stimulate hematopoietic cells and immune cells so as to not only improve immunity but also prevent and treat autoimmune disease and cancer.
- Hereinafter, the preferable experimental examples are provided for better understanding of the present invention. However, the present invention is not limited to the following experimental examples.
- [Experimental Example 1] Effects of Mono Acetyl Diacyl Glycerol Derivatives on T-Cell and Mononuclear Cell Proliferation
- [Experimental Example 1-1] Effects of Mono Acetyl Diacyl Glycerol Derivatives on T-Cell Proliferation
- Splenocytes were collected from C57BL/6 mice (provided from Asan Institute for Life Sciences Animal Lab., Seoul, Korea) spleens. Then, single cell suspensions were obtained by repeated aspiration and flushing. Red blood cells were removed using ammonium chloride and then passed through nylon wool to remove debris and clumps. T-cells were purified using magnetic bead (MACS bead, Miltenyi Biotec, bergich gladbach, Germany) containing anti-goat IgG MACS bead, Miltenyi Biotec, bergich gladbach, Germany) or anti-mouse CD4(MACS bead, Miltenyi Biotec, bergich gladbach, Germany) or anti-mouse CD8 antibody (MACS bead, Miltenyi Biotec, bergich gladbach, Germany) (Turner and Dockrell (1996) Immunology, 87: 339-342).
- T cell suspensions were suspended in Isocove's modified Dulbecco's medium (IMDM, Gibco, Grand Island, N.Y.) supplemented with 10% fetal bovine serum (referred as ‘FBS’ hereinafter) (Gibco, Grand Island, N.Y.). 5×104 viable cells per well were cultured in 96-well plates, with 1 μg/ml of
Compound 1,Compound 2, Compound 4 and Compound 5, 0.01, 0.1, 1 μg/ml of Compound 3(synthesized and provided by Department of Chemistry, Ewha Womans University, Seoul, Korea) or 20 ng/ml of IL-2. On the 6th day, cells were incubated with 1 μCi 3H-thymidine/well for 24 hours. On the 7th day, the cells were harvested and the incorporation Index (referred as ‘SI’ hereinafter) was calculated by the followingMathematical Formula 1. -
SI=3H-thymidine absorbed by wells of experimental group (CPM in sample)/3H-thymidine absorbed by wells of control group (CPM in control). [Mathematical Formula 1] - As a result, mono acetyl diacyl glycerol derivatives treated group had increased SI of T-cells by thymidine uptake of 2.05, which was similar to that of IL-2 treated group (Table 1).
-
TABLE 1 Treated group SI IL-2 (20 ng/ml)* 2.05 ± 0.24 Compound 1 (1 μg/ml)* 2.01 ± 0.43 Compound 2 (1 μg/ml)* 2.03 ± 0.54 Compound 3 (0.01 μg/ml)** 1.83 ± 0.32 Compound 3 (0.1 μg/ml)* 1.96 ± 0.18 Compound 3 (1 μg/ml)* 2.05 ± 0.64 Compound 4 (1 μg/ml)* 1.98 ± 0.26 Compound 5 (1 μg/ml)* 2.02 ± 0.38 *P < 0.05, **P < 0.005. All tests were done in triplicate and were repeated three times. - Effects of Mono Acetyl Diacyl Glycerol Derivatives on Monocytes Proliferation
- Monocytes were isolated from human whole blood using Histopaque 1077. And then, monocytes(5×106 cells/ml) were allowed to adhere to tissue culture flask for 3 hours in a 5% CO2 incubator. After 3 hours, non-adherent cells were removed and adherent cells were placed in 96-well plates in RPMI 1640 medium (GIBCO, Grand Island, N.Y.) supplemented with 10% FBS. 5×104 viable cells per well were cultured in 96-well plates, with 1 μg/ml of
Compound 1˜5. On the 6th day, cells were incubated with 1 μCi 3H-thymidine/well for 24 hours. On the 7th day, the cells were harvested and the incorporation of 3H-thymidine was measured. SI was calculated by the above mentionedformula 1. As a result,Compound 1˜5 treated group had increased monocytes SI 10.68, comparing to control, indicating that the compounds stimulated proliferation of monocytes (Table 2). -
TABLE 2 Treated group SI (± S.E) Non treated control 1 Compound 1 (1 μg/ml)* 9.97 ± 0.10 Compound 2 (1 μg/ml)* 10.42 ± 0.15 Compound 3 (1 μg/ml)* 10.68 ± 0.13 Compound 4 (1 μg/ml)* 10.21 ± 0.18 Compound 5 (1 μg/ml)* 9.75 ± 0.09 *P < 0.001, All tests were done in triplicate and were repeated two times. - Effects of
Compound 3 on T Cell Activity - Measurement of Cytokine by Elispot
- Elispot bioassay (ESAT-6 enzyme-linked immunospot assay) is a very sensitive quantification assay for detecting cytokine bound to the membrane because the bottom of each well of Elispot plates used in this assay was pre-coated with a cytokine specific antibody. Thus, Elispot assay was performed to measure the T cell activity. T-cells were seeded by 2×106cells to each well in a 24-well sterile tissue culture plate (Nunc, Denmark), followed by the treatment with 0.01, 0.1, 1 μg/ml concentrations of
Compound 3 or IL-2 (20 ng/ml). On the 7th day, cells were harvested and the cells were seeded by 5×105 cells/mg in multi-testplates (Elispot system kit, AID, Straberg, Germany) coated with the respective primary antibody (murine IL-2). After the plate was incubated for 24 hours in a 5% CO2 incubator, there was a secretion of cytokines by the cells, which were captured by the primary antibody (murine IL-2) determined by Elispot using commercially available mouse IL-2 Elispot kits according to the manufacturer's instructions. Each sample was tested in duplicate. Counting the number of IL-2 producing cells by Elispot is accomplished with Elispot reader (AID Elispot Reader System). The results showed thatCompound 3 treated group showed 1.52 folds increased T-4 activity, comparing to control group, and 1.46 folds increased of T-8 activity (FIG. 1 ). - Measurement of Cytokine by Bio-plex
- Bio-plex can measure huge amount of cytokine at a time in a well. Thus, Bio-plex kit was used to quantify 8 kinds of cytokines of Th1/Th2 channels, which are secreted when T-cells are activated. Sterilized 24-well tissue culture plate (Nunc, Denmark) was treated with anti-CD3 and anti-CD28. Then, the plate was inoculated with T-cells by 2×106cells/ml. In order to activate T-cells, 0.1, 1 μg/ml of
Compound 3 was treated thereto, followed by culture for 5 days. On the 5th day, culture solutions at each different stage were recovered, followed by centrifugation. Supernatants were obtained and cytokine secreted therein was quantified by using Bio-plex kit according to the manufacturer's instruction (Bio-rad). As a result, three kinds of cytokines(IL-2, IL-4, and IL-5), among 8 kinds of cytokines(IL-2, IL-4, IL-5, IL-10, IL-12, INF-γ, GM-CSF, TNF-α) were secreted in the group treated withCompound 3 and the amounts of them were bigger than those in a control group not treated with Compound 3 (FIG. 2 ). - T Cell Proliferation Assay
- The following experiment was performed to confirm the effect of
Compound 3 against immunocytes of the AIDS patients. First, Human mononuclear cells were obtained by Hisopaque 1077 from peripheral blood of AIDS patients. Red blood cells were removed using ammonium chloride and then passed through nylon wool to remove debris and clumps. T-cells were purified using magnetic bead (anti-human CD3)(MACS bead, Miltenyi Biotec, bergich gladbach, Germany). T cell suspensions were suspended in Isocove's modified Dulbecco's medium (IMDM, Gibco, Grand Island, N.Y.) supplemented with 10% fetal bovine serum (referred as ‘FBS’ hereinafter) (Gibco, Grand Island, N.Y.). 5×104 viable cells per well (in triplicate) were cultured in 96-well plates, with 0.01, 0.1, 1μg/ml concentrations ofCompound 3 or IL-2(20ng/m1). On the 6th day, cells were incubated with 1 μCi 3H-thymidine/well for 24 hours. On the 7th day, the cells were harvested and the incorporation of 3H-thymidine was measured. The SI (Stimulation Index) was calculated by the above mentionedformula 1. As a result, in AIDS patients, T cell proliferation assay, showedCompounds 3 treated group had 1.5 to 3.9 fold increase of T-cell stimulation index by thymidine uptake in all patients (4 out of 4) compared with control as seen in Table 3. Over all result of stimulation byCompound 3 was comparable with IL-2 stimulation. -
TABLE 3 Stimulation Index (SI) 1 2 3 4 IL-2 (20 ng/ml) 1.41 4.17 1.29 6.54 Compound 3 (1 μg/ml) 2.23 3.87 1.48 3.49 - Effects of
Compound 3 on the Expression of Adhesion Molecules of Dendritic Cells - Dendritic Cell Culture
- Bone marrow cells were obtained from the femurs and tibias of Balb/c AnN mice (Park, J. et al. (2003) J. Korean Med. Sci., 18: 372-380). The cells were washed 3 times in RPMI, and then mononuclear cells were obtained. These mononuclear cells were allowed to adhere to
tissue culture flask 3 hours in RPMI and 10% FBS. After incubation, the adherent cells(monocytes) were removed and non-adherent cells were placed in 100 mm tissue culture dishes, in a concentration of 1×105cells/ml in RPMI plus 10% FBS supplemented with 20 ng/ml murine rGM-CSF(R&D systems, Minneapolis, Minn., USA), 10 ng/ml, murine IL-4(R&D systems), and 2.5 ng/m1 murine TNF-α(R&D systems). Culture dishes were fed every 3 days. Murine TNF-α(R&D systems) was added at the 6th day of the culture. After that, murine TNF-α(R&D systems) was added every 3 days until on the 11th day. Mature dendritic cells were harvested for RT-PCR of adhesion molecule studies. As a result, when round shaped granulocytes were cultured for three days, those cells formed a cluster which was growing on the bottom of a well of cell culture plate, and mature dendritic cells were growing with forming a group on the 6th or the 7th day of culture. And on the 9th day of culture, dendritic cells formed a small but long protrusion specifically (FIG. 3 ). - Determination of Dendritic Cell Phenotype
- Those cells that were big and negative against trypan blue staining were counted and the morphology of each of them was investigated. 1×106 cells/ml were cultured and then washed, followed by fixation with 1% para-formaldehyde solution. Flow cytometric analysis of the fixed cells was performed by using FACScan (Beckton Dickinson, Mountain View, Calif., U.S.A), leading to the determination of the phenotype using antibodies against the following markers; isotype control against hamster IgG, rat IgG 2a, DC marker: DEC 205(NLDC-145) and CD 11C, co-stimulatory/adhesion molecule: CD 80(B7-1) and CD 86(B7-2), macrophage marker: CD 14 and F4/80, granulocyte marker: Gr-1 (Pharmingen, Hamburg, Germany). As a result, the levels of co-stimulation specific molecular markers CD80 and C86 and dendritic cell specific markers CD11C and DEC-205 were high. On the contrary, the levels of monocytes specific markers CD14 and F4/80 and granulocyte specific marker Gr-1 were low. The results indicate that the dendritic cells separated in the present invention have an exact phenotype of dendritic cells and the
purity 97 to 98% (FIG. 4 ). - Treatment and the Expression of Adhesion Molecules
- It is generally known that the cell-cell interaction is involved in stimulations of various hematopoietic cells and of immune cells. Thus, the present inventors tried to confirm whether or not
Compound 3 affects various adhesion molecules of the mentioned cells. Particularly, dendritic cells cultured in the above example were treated with 1 μg/ml ofCompound 3, and then RT-PCR was performed. - Following primers: Icam-1(SEQ. ID.
No 1 and No 2), Icam-2(SEQ. ID.No 3 and No 4), Vcam-1(SEQ. ID. No 5 and No 6), VLA-4(SEQ. ID.No 7 and No 8), VLA-5(SEQ. ID. No 9 and No 10), LFA-1(SEQ. ID. No 11 and No 12) and GAPDH(SEQ. ID. No 13 and No 14) were used for the RT-PCR. Reaction sets used herein was a mixed solution of 2 μl DNA, 10× buffer solution, 1.5 μl of MgCl2, 2 μl of dNTPs, 0.5 μl of forward primer, 0.5 μl of reverse primer, 0.2 μl of polymerase and 15.8 μl of distilled water. - Total RNA separated from dendritic cells and MS-5, low density cells cultured with oligo(dt)-primer, was reverse-transcribed, and PCR was performed at 94° for 30 seconds, 65° for 30 seconds and 72° for 50 seconds. PCR was performed 34 times at total, and PCR products were doubled every performance. The expressions of adhesion molecules such as Vcam-1, Icam-1, Icam-2, VLA-4, VLA-5, and LFA-1 were confirmed by RT-PCR. For the quantification, PCR with GAPDH was performed to confirm the corresponding cDNA. The results showed that the expressions of adhesion molecules, Icam-2, VLA-5, LFA-1 on
Compound 3 treated dendritic cells were significantly increased compared to a control (FIG. 5 ). - Study on Anti-Cancer Effect of the
Compound 3 Through Subcutaneous Injection (Local Model) and Intravenous Injection (Systemic Model) - Biliary Cancer Model in Hamster
- Six week old female Syrian golden hamsters (Harlan, Indianapolis, India, USA) were housed in specific pathogen free unit. 5×105 KIBG-5 cells (Molecular therapy, Vol. 3, No. 4, pp431-437) suspended in 1000 of RPMI 1640 serum-free medium were intravenously injected via femoral vein. And 5×105KIBG-5 cells suspended in 100a of RPMI 1640 serum-free medium were subcutaneously injected to the flank of the hamsters. Hamsters injected KIBG-5 were divided into following 7 groups;
- 1) Control group treated with RPMI medium,
- 2) Experimental group treated with non-modified BMSC cells (2.5×106)(Leukemia & Lymphoma, Vol.44, No. 11, pp1973-1978),
- 3) Experimental group treated with BMSC cells modified with Ad/
ΔE1 50 MOI(Leukemia & Lymphoma, Vol.44, No. 11, pp1973-1978), - 4) Experimental group treated with DC+tumor lysate(5×106),
- 5) Experimental group treated with BMSC cells modified with Ad/hIL-2 50 MOI(Leukemia & Lymphoma, Vol.44, No. 11, pp1973-1978),
- 6) Experimental group treated with BMSC cells modified with Ad/hIL-2 50 MOI+Experimental group treated with Compound 3(25mg/kg/day),
- 7) Experimental group treated with Compound 3(25 mg/kg/day).
- One week after the injection of cancer cells to hamsters (BMSC treated group), 2.5×106 of BMSC cells were injected once again to each hamster. In the case of DC+tumor lysate treated group, 5×106 of DC cells and tumor lysate were injected to each hamster (with subcutaneous injection or intravenous injection) at the first, second, third, forth, sixth, eighth week, followed by observation for 12 weeks. In the case of
Compound 3 treated group, one week before KIBG-5 cells injection, Compound 3(25 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 8 weeks. - As a result, 4 weeks after the cancer cell injection, tumor formed in RPMI treated group which was a control, BMSC treated group, and BMSC +Ad/ΔE1 treated group, but no tumor were found in DC+tumor lysate treated group,
Compound 3 treated group, and BMSC+Ad/IL-2 treated group(FIG. 6 ). Moreover, 8 weeks after the cancer cell injection, multiple metastatic lung lesions were found in RPMI treated group which was a control, BMSC treated group, and BMSC+Ad/ΔE1 treated group, and only one minute lung lesion was found in DC+tumor lysate treated group, andCompound 3 treated group. But no lesions were found in BMSC+Ad/IL-2 treated group (FIG. 7 , 8, 9). Further, 12 weeks after the cancer cell subcutaneous injection, tumor formed in RPMI treated group which was a control, BMSC treated group, BMSC+Ad/ΔE1 treated group, and DC+tumor lysate treated group, and less 5 mm sized tumor in one mice were found in BMSC+Ad/hIL-2 treated group but no tumor were found in BMSC +Ad/IL-2+ Compound 3 treated group (FIG. 10 ). - In another hand, six week old female Syrian golden hamsters were housed in specific pathogen free unit. KIGB-5 cells (5×105) suspended in 1000, of RPMI 1640 serum-free medium were intravenously injected via femoral vein. Hamsters were divided into following 4 groups: 1) PBS control group, 2) Compound 3 (10 mg/kg/day) treated group, 3) Compound 3 (25 mg/kg/day) treated group, 4) Compound 3 (50 mg/kg/day) treated group. One week before tumor cell injection, Compound 3 (10, 25 or 50 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 12 weeks. Animals of each group were sacrificed at 4, 8, 12 weeks for pathological examination. Gross findings at 4th week, tumor developed at injection site in control group, Compound 3 (10, 25 or 50 mg/kg/day) treated groups showed no evidence of tumor. At 8th week, control group observed multiple metastatic lesions in both lungs.
Compound 3 treated group (25, 50 mg/kg/day) did not show any metastatic lung lesions with naked eye, butCompound 3 treated group (25 mg/kg/day) showed one minute lesion with microscope.Compound 3 treated group (10 mg/kg/day) showed tumor in the left lung (FIGS. 11 and 12 ). - Melanoma Model in Mice(C57BL/6)
- 6 week female C57BL/6 mice (provided from Asan Institute for Life Sciences Animal Lab., Seoul, Korea) were housed in specific pathogen free unit.
- B16F10 cells (2×104) suspended in 100 μl of RPMI 1640 serum-free medium were intravenously injected via tail vein. One week before tumor cell injection, the following 3 groups were treated.
- 1) RPMI control group
- 2) Dendritic cells(DC)(5×105 cells/day)+tumor lysate treated group
- 3) Compound 3 (50 mg/kg/day) treated group.
- In the case of DC+tumor lysate treated group, one week before melanoma injection, 5×105 DC cells mixed with tumor lysate were injected to the abdominal cavity every 1 weeks. In the case of
Compound 3 treated group, 50 mg/kg/day ofCompound 3 was treated to each mouse. One week before melanoma(B16F10) injection, Compound 3(50 mg/kg/day) via P.O was continued 2 weeks on and 1 week off for 6 weeks. As a result, gross findings at 4th week control group observed multiple metastatic lesions in both lungs.Compound 3 treated group and DC +tumor lysate treated group showed no evidence of disease in the lung (FIG. 13 , 14) and showed 90% survival rate in the observation for 6 weeks after melanoma (B16F10) injection (FIG. 15 ). - Based on the presumption that the anti-cancer effects of the
Compound 3 are attributed to the activation of T-cells byCompound 3, cytotoxicity of T-cells activated byCompound 3 to malignant melanoma cells was investigated. As a result, when the ratio of T-cells activated byCompound 3 to melanoma cells was 100:1, cytotoxicity was 42% increased(FIG. 16 ). - Toxicity Test of
Compound 3 - Synthesized
Compound 3 was dissolved in 5% ethanol solution which was orally administered at the 0.1 ml/20 g dose. Control group was treated 5% ethanol solution. IRC mice, housed in SPF facility were used as test animals. The animals were fasted for one day before drug administration, and had free access to water and chow thereafter. Eight to ten ICR mice, 25-35 g of weight, were grouped. The test agent was orally administered once at increasing doses ranging from 62.5 mg/kg, 125 mg/kg, 250 mg/kgkg, 500 mg/kg, 1.0 g/kg, to 2.0 g/kg. From the day of administration, survival number and any abnormal signs were observed with the naked eye for 14 days. LD50 was calculated by the method of Lichfield-Wilcoxon ( - - —acute toxicity test, Realize Inc., Tokyo, 1988), and weight changes were calculated by the following Mathematical Formula.
-
Weight increment rate(%)={Weight of day 14—Weight of day 0}÷ {Weight of day 0}×100 [Mathematical Formula 2] - The results are shown in Table 4. No toxicity was seen with 62.5 mg/kg˜2 g/kg of
Compound 3. This observation indicated that LD50 was over 2 g/kg. Any abnormal sign as not observed with the naked eyes for 14 days after the administration. The weight of animals in treated group increased steadily so did in control animals. As shown in Table 5, no significant, treatment-specific weight change (gaining or losing) was observed. -
TABLE 4 Dosage of Compound 3 (mg/kg) 0 62.5 125 250 500 1000 2000 Number of dead mice/ 0/10 1/8 0/8 1/8 2/9 0/9 0/9 Number of orally administered mice LD50 0 12.5 30 12.5 22.2 0 0 -
TABLE 5 Weight increase 14 days after the oral-administration of Compound 3Dosage of Compound 3 (mg/kg) 0 63 125 250 500 1000 2000 Weight 14 days after 38.7 ± 1.1 34.3 ± 0.1 38.1 ± 1.3 35.6 ± 1.4 36.5 ± 1.9 35.5 ± 1.1 35.9 ± 2.7 Administration (g) Weight increment rate (%) 16.9 11.9 17.3 11.2 10.1 9.5 14.4 - Long term hepatotoxicity test was done on rats with
Compound 3 dose at 100 mg/kg body weight/day given P.O. for 4 weeks, and liver function test, lipid profile, cytochrome C-450 activity were observed. At the end of 4 weeks liver histology was observed. No significantly adverse effect was observed. - CLP (Cecal Ligation and Puncture) Test
- CLP test was performed in order to confirm the effect of
Compound 3 for prevention and treatment against septic shock. Ten 7-10 week old male inbred C3H/HeN mice(20-25 g of weight) were grouped. After 50 mg/kg/day ofCompound 3 was orally administered to mice for 2 weeks on and 1 week off, mice were anesthetized with 80 mg/kg of ketamine and 16 mg/kg of rompun. Septic shock was induced by CLP model in anesthetized mice. One hour after inducing septic shock, 50 mg/kg ofCompound 3 was treated, and then, the same treatment was continued for 3 days every 24 hours. Control group was orally administered PBS+5% ethanol solution. Survival rate ofCompound 3 treated group and control group with time lapse was shown in Table 6.Compound 3 treated groups had 100% survival rate even after lapse of 120 hours. -
TABLE 6 Survival rate in septic shock Survival rate with time lapse 0 hour 24 hours 48 hours 72 hours 96 hours 120 hours Survival Survival Survival Survival Survival Survival rate rate rate rate rate rate PBS treated group 100% 60% 40% 40% 40% 40% (control) Compound 3100% 100% 100% 100% 100% 100% (50 mg/kg) - Preparation of Medical
Supplies Containing Compound 3 as an Effective Ingredient - After confirming through the above experiments that
Compound 3 had an excellent immunomodulating and anti-cancer activity, the present inventors prepared atreatment containing Compound 3 as an effective ingredient. Further, the followed manufacturing example of thetreatment containing Compound 3 as an effective ingredient can be applied not only to the preparing of treatment but also to the preparing of health food. If there isn't extra mention, the symbol of % means weight % in the following manufacturing example. - Preparation of Soft Gelatin Capsules
-
-
Compound 330% Vitamin C 4.5% Vitamin D3 0.001% Manganese sulfate 0.1 % Wax 10 % Palm oil 25% Safflower oil (Carthamus tinctorius) 30.399% -
-
Compound 331.25% Evening primrose seed oil 59.75% Soy oil 6.7% Vitamin E acetate ester (DL-α-tocopherol acetate) 2.1% Soy lecithin 0.2% -
-
Compound 398.0% Vitamin E acetate ester (DL-α-tocopherol acetate) 2.0% - Preparation of Tablets
-
Compound 330 % Vitamin C 10% Vitamin D3 0.001% Manganese sulfate 0.1% Crystalline cellulose 25.0% Lactose 32.999 % Magnesium Stearate 2% - Preparing of an Injection Formulation
-
Compound 32% Propylene glycol 35% Mono glyceride 8% Ethanol 5 % Water 50% - The injection formulation was prepared by the conventional method with above mentioned compositions and contents.
- Preparation of Medical
Supplies Containing Compound - Soft gelatin capsules, tablets and injection suspension were prepared by the same method and composition as described in the above manufacturing example 1, except the
Compound 3 was substituted withCompound - Preparation of Health
Food Containing Compound 3 as an Effective Ingredient - After confirming through the above examples that the
Compound 3 had an excellent immunomodulating, anti-septic shock, and anti-cancer activity, the present inventors prepared health food containing the same as an effective ingredient. - Preparation of Beverages
-
Honey 522 mg Thioctic amide 5 mg Nicotinic amide 10 mg Sodium riboflavin hydrochloride 3 mg pyridoxine hydrochloride 2 mg Inositol 30 mg Ortho acid 50 mg Compound 3 0.48~1.28 mg water 200 ml - Beverage was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Chewing Gum
-
Gum base 20% Sugar 76.36~76.76 % Compound 3 0.24~0.64 % Fruit flavor 1 % Water 2% - Chewing gum was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Candy
-
Sugar 50~60% Starch syrup 39.26~49.66 % Compound 3 0.24~0.64% Orange flavor 0.1% - Candy was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Biscuit
-
Strong flour 1st class88 kg Cake flour 1st class 76.4 kg Refined sugar 16.5 kg Salt 2.5 kg Glucose 2.7 kg Palm shortening 40.5 kg Ammo 5.3 kg Baking soda 0.6 kg Sodium bisulfate 0.55 kg Rice flour 5.0 kg Vitamin B1 0.003 kg Vitamin B2 0.003 kg Milk flavor 0.16 kg Water 71.1 kg Whole milk powder 4 kg Substitute milk powder 1 kg Calcium phosphate, monobasic 0.1 kg Spraying salt 1 kg Spraying milk 25 kg Compound 3 0.2~0.5 kg - Biscuit was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Ice Cream
-
Milk fat 10.0% Milk solids non-fat 10.8% Sugar 12.0% Starch syrup 3.0% Emulsifying stabilizer (span) 0.5% Flavor (Strawberry) 0.15% Water 63.31~62.91 % Compound 3 0.24~0.64% - Ice cream was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Chocolate
-
Sugar 34.36~34.76% Cocoa butter 34% Cocoa mat 15% Cocoa powder 15% Lecithin 0.5% Vanilla flavor 0.5 % Compound 3 0.24~0.64% - Chocolate was prepared based on the above compositions and contents by following a conventional method.
- Preparation of Health
Food Containing Compound - Beverage, chewing gum, candy, biscuit, ice cream and chocolate were prepared by the same method and composition as described in the above manufacturing example 3, except the
Compound 3 was substituted withCompound - Advantageous Effects
- As explained hereinbefore, the mono acetyl diacyl glycerol
derivatives containing Compound 3 shows significant effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against caner cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect of apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer. - While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (2)
1. A method of treating cancer comprising administering to a mammal an effective amount of a mono acetyl diacyl glycerol derivative of formula I:
2. The method of claim 1 , wherein the cancer is selected from the group consisting of bile duct cancer, kidney cancer and malignant melanoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/640,875 US20100137435A1 (en) | 2004-04-24 | 2009-12-17 | Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2004-0028514 | 2004-04-24 | ||
KR20040028514 | 2004-04-24 | ||
KR1020040070650A KR20050118057A (en) | 2004-04-24 | 2004-09-04 | Anti-cancer agent and health food containing acethyldiacylglycerole derivatives as an effective ingredient |
KR10-2004-0070650 | 2004-09-04 | ||
KR10-2004-0109805 | 2004-12-21 | ||
KR1020040109805A KR20050118095A (en) | 2004-04-24 | 2004-12-21 | Immunity enhancing agent, anti-cancer agent, and health food containing acethyldiacylglycerole derivatives as an effective ingredient |
US11/587,377 US7662853B2 (en) | 2004-04-24 | 2005-04-22 | Monoacetyldiacylglycerol derivative for the treatment of sepsis |
PCT/KR2005/001175 WO2005112912A1 (en) | 2004-04-24 | 2005-04-22 | Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives |
US12/640,875 US20100137435A1 (en) | 2004-04-24 | 2009-12-17 | Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2005/001175 Division WO2005112912A1 (en) | 2004-04-24 | 2005-04-22 | Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives |
US11/587,377 Division US7662853B2 (en) | 2004-04-24 | 2005-04-22 | Monoacetyldiacylglycerol derivative for the treatment of sepsis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100137435A1 true US20100137435A1 (en) | 2010-06-03 |
Family
ID=37291279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/587,377 Active 2025-07-17 US7662853B2 (en) | 2004-04-24 | 2005-04-22 | Monoacetyldiacylglycerol derivative for the treatment of sepsis |
US12/640,875 Abandoned US20100137435A1 (en) | 2004-04-24 | 2009-12-17 | Monoacetyldiacylglycerol Derivative for the Treatment of Sepsis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/587,377 Active 2025-07-17 US7662853B2 (en) | 2004-04-24 | 2005-04-22 | Monoacetyldiacylglycerol derivative for the treatment of sepsis |
Country Status (5)
Country | Link |
---|---|
US (2) | US7662853B2 (en) |
JP (1) | JP4892473B2 (en) |
KR (1) | KR20050118057A (en) |
CN (1) | CN1946392B (en) |
RU (1) | RU2341257C2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015176012A1 (en) * | 2014-05-15 | 2015-11-19 | Enzychem Lifesciences Corporation | Methods for treating leukopenia and thrombocytopenia |
EP3042651A4 (en) * | 2013-09-03 | 2017-04-26 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis |
KR101781993B1 (en) | 2015-11-09 | 2017-09-26 | 주식회사 엔지켐생명과학 | A composition for treating mucositis |
RU2642631C2 (en) * | 2013-08-19 | 2018-01-25 | Энзикем Лайфсайенсиз Корпорейшн | Composition for prevention or treatment of chronic obstructive pulmonary diseases containing monoacethyldiglycerol compounds as active ingredient |
US9895337B2 (en) | 2013-08-19 | 2018-02-20 | Enzychem Lifesciences Corporation | Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis |
US10098864B2 (en) | 2013-08-19 | 2018-10-16 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma |
US20190350890A1 (en) * | 2016-10-13 | 2019-11-21 | Enzychem Lifesciences Corporation | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound |
WO2020148562A1 (en) * | 2019-01-16 | 2020-07-23 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
WO2020212915A1 (en) * | 2019-04-16 | 2020-10-22 | Enzychem Lifesciences | Compositions and methods for treating diabetes |
WO2023067501A1 (en) * | 2021-10-18 | 2023-04-27 | Enzychem Lifesciences Corporation | Compositions and methods for treating mucositis |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100010087A1 (en) * | 2008-07-10 | 2010-01-14 | Hong John J | Methods for Inducing Stem Cell Migration and Specialization with EC-18 |
US20100227021A1 (en) * | 2009-03-06 | 2010-09-09 | Woodland Outdoor Group, Llc | Deer food formulations and related methods |
MD3972C2 (en) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remedy and method for treating precancerous conditions |
KR101278874B1 (en) * | 2011-09-23 | 2013-06-26 | 주식회사 엔지켐생명과학 | Method for preparing of 1-palmitoyl-3-acetylglycerol and Method for preparing of 1-palmitoyl-2-linoleoyl-3-acetyl glycerol using the same |
RU2496871C1 (en) * | 2012-08-09 | 2013-10-27 | Сергей Владимирович Осутин | Method to extract stem cells from bone marrow for intravascular introduction |
CN110327324A (en) | 2013-08-19 | 2019-10-15 | Enzychem生命科学株式会社 | Contain the leukemia or metastasis of cancer inhibition composition using mono acetyl diacyl glycerol compound as effective component |
US20160279088A1 (en) * | 2013-09-17 | 2016-09-29 | Enzychem Lifesciences Corporation | Composition for promoting differentiation or proliferation of erythrocytic cells, containing monoacetyl diacylglycerol compound as active ingredient |
SI3205720T1 (en) * | 2014-10-09 | 2020-01-31 | Yamaguchi University | Car expression vector and car-expressing t cells |
JP6113133B2 (en) * | 2014-11-06 | 2017-04-12 | 日本メナード化粧品株式会社 | Stem cell undifferentiated state maintenance agent and growth promoter |
KR101836822B1 (en) * | 2016-10-17 | 2018-03-09 | 주식회사 엔지켐생명과학 | Composition for preventing or treating psoriasis comprising monoacetyl-diacylglycerol compound |
PL3716967T3 (en) | 2017-11-30 | 2023-12-11 | Enzychem Lifesciences Corporation | Compositions for prevention or treatment of acute radiation syndrome |
KR20190063536A (en) * | 2017-11-30 | 2019-06-10 | 주식회사 엔지켐생명과학 | Composition for preventing or treating acute radiation syndrome comprising 1-palmitoyl-2-linoleoyl-3-acetylglycerol |
KR102176809B1 (en) * | 2018-10-11 | 2020-11-10 | 몸엔용바이오 농업회사법인 주식회사 | A Composition Comprising the combined herbal extract of Deer antlers and Acanthopanax senticosus HARMS for immuno-stimulating activity |
KR102218540B1 (en) * | 2019-04-16 | 2021-02-22 | 주식회사 엔지켐생명과학 | Composition for treating diabetes containing monoacetyldiacylglycerol compound and method for treating diabetes |
JP2022553421A (en) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | Methods and compositions for treating cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040010290A1 (en) * | 1999-04-09 | 2004-01-15 | Schroeppel Edward A. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
US20040110932A1 (en) * | 1999-03-09 | 2004-06-10 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6212716A (en) * | 1985-07-11 | 1987-01-21 | Nippon Oil & Fats Co Ltd | Carcinostatic agent |
GB9116054D0 (en) * | 1991-07-24 | 1991-09-11 | Efamol Holdings | Preparation of fatty acid medicaments |
DE69306545T2 (en) * | 1992-10-01 | 1997-04-03 | Wellcome Found | Tucaresol as an immunopotentiator |
DE4330664A1 (en) * | 1993-09-10 | 1995-03-16 | Beiersdorf Ag | Uses of vegetable oils |
JPH0827010A (en) * | 1994-07-19 | 1996-01-30 | Nichinichi Seiyaku Kk | Carcinostatic immunotherapeutic agent |
WO1999026640A1 (en) | 1997-11-20 | 1999-06-03 | Bukwang Pharm. Ind. Co., Ltd. | Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes |
US20020188024A1 (en) * | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
US20030032674A1 (en) * | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
KR20050103259A (en) | 2004-04-24 | 2005-10-27 | 김상희 | Anti-cancer agent containing interleukin-2 and monoacethyldiglyceride-3 as an effective ingredient |
-
2004
- 2004-09-04 KR KR1020040070650A patent/KR20050118057A/en active Search and Examination
-
2005
- 2005-04-22 CN CN2005800129149A patent/CN1946392B/en active Active
- 2005-04-22 RU RU2006141418A patent/RU2341257C2/en active
- 2005-04-22 JP JP2007509400A patent/JP4892473B2/en active Active
- 2005-04-22 US US11/587,377 patent/US7662853B2/en active Active
-
2009
- 2009-12-17 US US12/640,875 patent/US20100137435A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040110932A1 (en) * | 1999-03-09 | 2004-06-10 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
US20040010290A1 (en) * | 1999-04-09 | 2004-01-15 | Schroeppel Edward A. | Method and device for treating cancer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895337B2 (en) | 2013-08-19 | 2018-02-20 | Enzychem Lifesciences Corporation | Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis |
US11135193B2 (en) | 2013-08-19 | 2021-10-05 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma |
US10098864B2 (en) | 2013-08-19 | 2018-10-16 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma |
RU2642631C2 (en) * | 2013-08-19 | 2018-01-25 | Энзикем Лайфсайенсиз Корпорейшн | Composition for prevention or treatment of chronic obstructive pulmonary diseases containing monoacethyldiglycerol compounds as active ingredient |
EP3042651A4 (en) * | 2013-09-03 | 2017-04-26 | Enzychem Lifesciences Corporation | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis |
RU2702122C2 (en) * | 2014-05-15 | 2019-10-04 | Энзикем Лайфсайенсиз Корпорейшн | Methods of treating leukopenia and thrombocytopenia |
AU2015258840B2 (en) * | 2014-05-15 | 2018-03-15 | Enzychem Lifesciences Corporation | Methods for treating leukopenia and thrombocytopenia |
WO2015176012A1 (en) * | 2014-05-15 | 2015-11-19 | Enzychem Lifesciences Corporation | Methods for treating leukopenia and thrombocytopenia |
US10588886B2 (en) | 2014-05-15 | 2020-03-17 | Enzychem Lifesciences Corporation | Methods for treating neutropenia |
US10596141B2 (en) | 2014-05-15 | 2020-03-24 | Enzychem Lifesciences Corporation | Methods for treating thrombocytopenia |
US11357749B2 (en) | 2014-05-15 | 2022-06-14 | Enzychem Lifesciences Corporation | Methods for treating neutropenia |
US11491132B2 (en) | 2014-05-15 | 2022-11-08 | Enzychem Lifesciences Corporation | Methods for treating thrombocytopenia |
US9808438B2 (en) * | 2015-11-09 | 2017-11-07 | Enzychem Lifesciences Corporation | Method for treating mucositis |
KR101781993B1 (en) | 2015-11-09 | 2017-09-26 | 주식회사 엔지켐생명과학 | A composition for treating mucositis |
US20190350890A1 (en) * | 2016-10-13 | 2019-11-21 | Enzychem Lifesciences Corporation | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound |
WO2020148562A1 (en) * | 2019-01-16 | 2020-07-23 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
WO2020212915A1 (en) * | 2019-04-16 | 2020-10-22 | Enzychem Lifesciences | Compositions and methods for treating diabetes |
WO2023067501A1 (en) * | 2021-10-18 | 2023-04-27 | Enzychem Lifesciences Corporation | Compositions and methods for treating mucositis |
Also Published As
Publication number | Publication date |
---|---|
KR20050118057A (en) | 2005-12-15 |
RU2341257C2 (en) | 2008-12-20 |
US20080200543A1 (en) | 2008-08-21 |
US7662853B2 (en) | 2010-02-16 |
JP2007534681A (en) | 2007-11-29 |
RU2006141418A (en) | 2008-05-27 |
CN1946392B (en) | 2010-12-29 |
CN1946392A (en) | 2007-04-11 |
JP4892473B2 (en) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7662853B2 (en) | Monoacetyldiacylglycerol derivative for the treatment of sepsis | |
EP1740169B1 (en) | Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives | |
Liu et al. | Antitumor effects of the partially purified polysaccharides from Antrodia camphorata and the mechanism of its action | |
US8258188B2 (en) | Method of using punicic acid to enhance immune response and prevent metabolic disorders | |
KR101621856B1 (en) | Composition for treating rheumatoid arthritis comprising monoacetyldiacylglycerol compound and method for treating rheumatoid arthritis using the same | |
US20090318567A1 (en) | Lycopene for the treatment of metabolic dysfunction | |
US20150174186A1 (en) | Pharmaceutical composition for preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredient | |
EP3527206A2 (en) | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound | |
EP1734946B1 (en) | Punicic acid for use to enhance immune response and treating inflammatory bowel disease | |
KR100605114B1 (en) | Composition comprising Notoginseng Radix extract for preventing and treating of arthritis as an effective component | |
KR100605116B1 (en) | Composition comprising Notoginseng Radix extract for preventing and treating of periodentitis as an effective component | |
KR20160108771A (en) | Composition for preventing or treating liver disease comprising sarcodon asparatus extract | |
JP4585172B2 (en) | Bone formation promoter | |
WO2015041458A1 (en) | Composition for promoting differentiation or proliferation of erythrocytic cells, containing monoacetyl diacylglycerol compound as active ingredient | |
KR20050118095A (en) | Immunity enhancing agent, anti-cancer agent, and health food containing acethyldiacylglycerole derivatives as an effective ingredient | |
JP3246683B2 (en) | Cell growth promoting substance and composition containing the same | |
CN114177185B (en) | A pharmaceutical composition for reducing cholesterol and preventing cardiovascular diseases | |
US20230123101A1 (en) | Anti-obesity composition and composition for oral administration | |
S Abd El-Baky et al. | Effect of Some Plant leaves extract on diabetic rats | |
KR20160014888A (en) | A Use of Ginsenoside for Improving an immuno-Reaction induced by Cyclosporine | |
CN113244405A (en) | Pharmaceutical composition of forskolin/isoforskolin and pentacyclic triterpenoid and application thereof | |
Anggraeny et al. | P re-Proof | |
Rhule | Effects of the medicinal herb, Panax notoginseng, on the fate and function of professional antigen presenting cells | |
JP2010254718A (en) | Bone formation accelerator | |
WO2013081452A1 (en) | Phosphatidylinositol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |